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Cytotoxic drugs like docetaxel and doxorubicin play a vital role in breast 
cancer therapy. However their usefulness is limited by a common drawback: 
drug resistance. In addition to accumulating evidence indicating a role of 
TFF3 in oncogenicity of several carcinomas, TFF3 has been revealed to be 
involved in drug resistance. It has been observed that TFF3 is upregulated 
after chemotherapy in some clinical studies. In addition, it has been 
demonstrated that TFF3 mediates anti-estrogen resistance in human mammary 
carcinoma.  
This study demonstrated that TFF3 mediated cytotoxic drug resistance in 
mammary carcinoma cells. TFF3 promoted colony formation in soft agar and 
cell growth in 3D Matrigel of MCF-7 cells in a BCL-2 dependent manner. 
Forced expression of TFF3 reduced docetaxel and doxorubicin sensitivity in 
MCF-7 cells. Conversely, depletion of TFF3 with siRNA increased docetaxel 
sensitivity. Furthermore, expression of TFF3 was upregulated in mammary 
carcinoma cells with acquired docetaxel resistance and its expression was 
further induced by docetaxel treatment.  
Given the vital role of TFF3 in oncogenicity of mammary carcinoma as well 
as drug resistance to chemotherapeutic agents, TFF3 may represent a potential 
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Chapter 1 Introduction 
1.1 Hallmarks of cancer and therapeutic targeting 
The development of human tumors is a complex and multistep process.  
Understanding the mechanisms underlying cancer development may provide a 
basis for improvement in cancer therapies.  
 
1.1.1 Hallmarks of cancer 
In 2000, Hanahan and Weinberg proposed six hallmarks of cancer, which 
provided a logical framework for understanding the complexities of neoplastic 
disease. These hallmarks include sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis (Hanahan and 
Weinberg 2000, Hanahan and Weinberg 2011). 
a. Sustaining proliferative signaling  
In cancer cells, the growth signals that are normally strictly controlled become 
deregulated. Sustaining proliferative signaling favors cancer cells in cell cycle 
progression, cell growth as well as cell survival and energy metabolism. 
Tumor cells can acquire this capability through several alternative ways 
including synthesis of growth factor ligands by themselves, stimulation of 
normal cells that reciprocate by supplying growth factors to cancer cells, 
elevating the levels of receptors, structural alterations in the receptors to 
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facilitate ligand-independent firing, and activation of components downstream 
of these receptors (Hanahan and Weinberg 2011).  
b. Evading growth suppressors  
In addition, cancer cells need to overcome the negative regulations of cell 
proliferation. A frequent mechanism of evading growth suppressors is the 
mutation of suppressor genes. Retinoblastoma (RB) and tumor protein 53 (p53) 
are two key suppressor proteins that act as central molecules in cellular 
circuits that regulate the proliferation or apoptosis of cells (Burkhart and Sage 
2008, Hanahan and Weinberg 2011).    
c. Resisting cell death  
Apoptosis is another key mechanism against the development of cancer cells. 
Mutation in B-cell lymphoma 2 (BCL-2), autophagy and necrosis may 
contribute to resistance to cell death and promote tumor growth (Adams and 
Cory 2007, Hanahan and Weinberg 2011).  
d. Enabling replicative immortality 
Normal cells have limited number of doubling while tumor cells require 
unlimited replicative potential to generate macroscopic tumors. Telomeres 
protecting the ends of chromosomes are centrally involved in the capability of 
enabling replicative immortality (Blasco 2005).   
e. Inducing angiogenesis 
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The tumor-associated neovasculature, generated by the inducing angiogenesis 
address the need transporting oxygen and nutrition as well as the evacuating 
carbon dioxide and metabolic wasters.  
f. Activating invasion and metastasis 
Primary cancers account for only a small part of cancer deaths. Activation of 
invasion and metastasis enables tumor cells to establish secondary tumors in 
distant sites. Broadly, invasion and metastasis are regulated by the 
epithelial-mesenchymal transition (EMT).    
Besides the six hallmarks of cancer proposed in 2000, there have been 
additional hallmarks and characteristics recently as shown in Figure1.1. One 
of the new hallmarks, deregulating of cellular energetics allows the cells to 
modify cellular metabolism in order to support tumor proliferation. The other 
is avoiding immune destruction. This capacity protects cells from 
immunological destruction, in particular by T and B-lymphocytes, 
macrophages, and natural killer cells.  Since these two capacities are not fully 
validated, they are termed as emerging hallmarks. In addition, two 
characteristics of cancer facilitate the acquisition of these hallmarks. 
Acquisition of the multiple hallmarks depends in a large part on the genome 
instability and mutation, which drives tumor progression. Inflammation 
produced by innate immune cells can support cancer hallmark capabilities, 
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resulting in tumor-promoting consequences, which is called tumor-promoting 




Figure 1.1 Therapeutic targeting of the hallmarks of cancer (Hanahan and 
Weinberg 2011). Drugs are developed as targeted therapies towards different 
capabilities necessary for growth and progression of tumor. Some of the drugs 
are in clinical trials while some others have been approved for clinical use in 




1.1.2 Therapeutic targeting  
Development in understanding of hallmark capabilities and the multiple 
pathways supporting them can benefit cancer therapy development. Based on 
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the remarkable development in understanding of cancer pathogenesis, novel 
targeted therapies have been introduced to the treatment of multiple human 
cancers. Usually, these therapies act directly towards specific molecular 
targets. They can be grouped according to their respective effects in one or 
more hallmark capacities. Some examples are presented in Figure 1.1.   
Currently, drugs of targeted therapies are developed to target specific 
molecules involved in enabling particular cellular capabilities. Such specificity 
results in less nonspecific toxicity and fewer off-target effects while leading to 
transitory responses followed by almost-inevitable relapses (Hanahan and 
Weinberg 2011). 
Usually, inhibiting one key pathway by a targeted therapeutic agent may not 
completely block a certain hallmark capability. Given that the number of key 
pathways supporting this capability is limited, it is possible to prevent 
acquired resistance by inhibiting all the key pathways. There is another 
specific form of adaptive drug resistance. Cancer cells may reduce dependence 
on a particular hallmark capability, becoming more dependent on others in 
response to targeted therapy. Such shifts in dependence can limit the 
efficiency of targeted therapies (Hanahan and Weinberg 2011). 
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1.2 Breast cancer 
By definition, breast cancer is a type of cancer originating from breast tissues. 
Breast cancer occurs in humans and other mammals. In human breast cancer 
cases, while the overwhelming majority of breast cancer occurs in women, 
male breast cancer can also occur. It is the most common cancer among 
female cancers worldwide (Globocan 2008, WHO).  
1.2.1 Mammary gland: Structure and development  
The mammary gland is a unique organ to the class of Mammalia, which is 
responsible for providing nutrition to the young.  
The parenchyma and the adipose stroma are the two primary components of 
mammary gland. The parenchyma forms a system of branching ducts from 
which secretory acini develop (Medina 1996). The adipose stroma provides a 
substrate for the parenchyma to develop and function. Each of the mammary 
gland consists of 15-20 lobes. Each lobe is composed of a series of branched 
ducts that drain into the nipple. The duct is lined with a layer of epithelial, 
which are responsible for milk production (Figure 1.2). An outer layer of 
myoepithelial cells with contractile properties surrounds these structures. The 
ducts are embedded in fibroblast stroma (Ali and Coombes 2002). 
The development of the mammary gland can be divided into distinct stages 
related to sexual development and reproduction: fetal, postnatal, postpubertal 
and pregnancy.  
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Mammary gland development starts during embryogenesis. The earliest signs 
of mammary specific progenitor cells are seen at weeks 4-5 of the human fetus. 
By the completion of fetal development, the primary duct, which is lined by a 
two cells thick epithelial layer, branches to form secondary ducts lined by a 
single layer of epithelial cells (Medina 1996).  Male and female have a 
similar rudimentary mammary gland at birth.  
Following embryonic development, the development of female mammary is 
initiated with the onset of the puberty. This process is dependent on the high 
level of estrogen produced by the ovary, progesterone, as well as growth 
hormone during puberty. As a result, the mitotic activity in the mammary 
gland leads to the elongation of the terminal end bud (TEB), which arise from 
pluripotent stem cells presented in the ductal tree (Williams and Daniel 1983). 
It has been demonstrated that estrogen, growth hormone and insulin like 
growth factor-1 are the key endocrine signals mediating mammary gland 
development (Kleinberg 1997).  
After puberty, regulated by the menstrual cycle, the mammary gland 
undergoes cycles of growth. Postpubertal development results in cyclical 
increase in ductal branching, leads to a ductal tree that fills the adipose stroma.  
During pregnancy, the hormones of pregnancy initiate the growth of 
mammary gland. This phase of development involves a rapid and intense 
proliferative activity and alveolar differentiation. Upon completion of lactation, 
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the mammary gland regresses to near prepregnancy state through apoptosis of 
epithelial cells and redevelopment of adipose tissue of the mammary gland.   
 
                              
 
Figure 1.2 Anatomy of the normal female breast tissue [from PubMed 
Health]. Each mammary gland contains 15-20 lobes, each lobe containing a 
series of branched ducts that drain into the nipple.  
 
 
1.2.2 Breast cancer incidence: Worldwide and Singapore 
Breast cancer is the most frequent cancer among women and ranks second 
among all types of cancer (Globocan 2008, WHO). Breast cancer is the top 
female cancer both in developed and developing countries. The incidence of 
breast cancer is quite high in western countries while relatively low in most of 
the developing regions. However, the incidence of breast cancer is increasing. 
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Breast cancer is the fifth cause of death from all cancer death cases and the 
most common cause of cancer death in women (Globocan 2008, WHO).  
According to the Singapore Cancer registry, breast cancer has been the most 
common cancer among females in Singapore for more than four decades. 
Breast cancer accounts for 29.3% of all female cancers for the period 
2006-2010 (Trends in Cancer Incidence in Singapore 2006-2010, NRDO).  
In Singapore, there are 7781 new cases of breast cancer during this period. 
The lifetime risk for breast cancer is 6.45%. The age-standardized incidence 
rate of newly diagnosed female breast cancer increased three fold in 
2006-2010 (NRDO 2012). Increasing effort in breast cancer screening and 
awareness in the society may have contributed to the increasing incidence in 
breast cancer.  Singapore is diverse country with different ethnic groups. 
Among the ethnic groups, the incidence rate is highest among Chinese women. 
However, in the last decade, there is a higher increase in breast cancer 
incidence among the Malays (Lim et al. 2012). The age-specific incidence rate 
increased sharply from age 30 onwards and peaked in the 60-69 age’s group. 
The incidence rate gradually declined in the 70 and above age groups (NRDO 
2012).  
Although breast cancer is still the leading cause of female cancer death, it is a 
relief to see the age-standardized 5-year observed survival rate for breast 
cancer increased (NRDO 2012).  The improvement in breast cancer survival 
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may have benefited from the advances in cancer treatment and early detection 
of breast cancer.    
 
1.2.3 Breast cancer risk factors 
There are some proposed risk factors contributing to the development of breast 
cancer. The incidences of breast cancer vary among different regions with up 
to 5-fold lower incidence in Eastern Asia than in Western countries. The 
variation probably related to environmental rather than genetic factors 
(Probst-Hensch et al. 2000). The incidence rate of breast cancer increases with 
age. The rate doubles about every 10 years. Many of the established risk 
factors are related to hormone due to their significant effects on cell growth, 
differentiation and function in the mammary gland and other tissues. These 
factors include increased hormone exposure with early menarche, late 
menopause, hormonal replacement therapy, having the first child after 30, and 
having no children. Other lifestyle related factors like alcohol consumption, 
postmenopausal obesity，sedentary lifestyle are suggested to be associated 
with increased risk of breast cancer, while young age at first pregnancy, 
prolonged lactation, and physical exercise are associated with a reduced risk 
(NRDO 2012, Feigelson HS and Henderson BE 2001). Family history of 
breast cancer is also one of the risk factors. Risk ratios increase with 
increasing numbers of affected first-degree relatives (Baselga and Norton 
2002).  
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Breast cancer results from multiple factors, which lead to the accumulation of 
mutation in essential genes. Genetic risk factors in the familial and hereditary 
forms of breast cancer include mutations in Breast Cancer gene 1 (BRCA1), 
BRCA2 and other genes. Hereditary breast cancer accounts represents less 
than 10% of all cases. Germline mutations in BRCA1 and BRCA2 account for 
40% of strongly familial breast cancer cases (Shuen and Foulkes 2011). 
BRCA1 is an important regulator of genomic integrity with multiple roles in 
homologous repair, checkpoint control, spindle regulation and transcriptional 
regulation. BRCA2 regulates critical step in homologous repair- RAD51 
filament formation. BRCA2 binds to ssDNA, facilitates loading of RAD51 at 
both dsDNA junction and ssDNA but inhibits RAD51 binding to dsDNA, 
while stabilizing RAD51 multimers for strand invasion and homologous 
(Shuen and Foulkes 2011). BRCA1 mutation is associated with a 65-81% 
lifetime risk for breast cancer. While in the case of BRCA2, the lifetime risk is 
45-85% (Euhus 2011). Mutations in p53, p16, CHK2, PTEN, LKB1, 
E-cadherin, ATM, BRIP1 and PALB2 are also associated with increased risk 
of breast cancer, although very rare (Euhus 2011).  
 
1.2.4 Detection of breast cancer 
Screening and early detection of breast cancer could improve the outcome and 
survival of the patients. A number of tests including physical exam, 
mammogram, genetic screening, Ultrasound, Magnetic resonance imaging 
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(MRI), and Biopsy have been established for the screening and diagnosis of 
breast cancer. For breast cancer positive cases, estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor type 2 
receptor (HER2) tests can be done to further determine the best choice of 
treatment.  
 
1.2.5 Treatment of breast cancer 
Breast cancer is the fifth cause of death from all cancer death cases (Globocan 
2008, WHO). Due largely to the improvement in breast cancer diagnosis and 
treatment, the survival rate has risen. The overall 5-year relative survival rate 
for female breast cancer patients has improved from 75.1% between 1975 and 
1977 to 90.0% for 2001 through 2007 in the USA (Siegel et al. 2012).  
 
1.2.5.1 Main therapies in breast cancer treatment  
Like other cancers, the treatment for breast cancer includes surgical treatment, 
radiation and chemotherapy. The treatment utilized in different breast cancer 
patients is highly dependent on the stage, molecular subtypes of breast cancer 
(e.g. ER and HER 2 status) and other characteristics. Surgery for breast cancer 
involves breast-conserving surgery (BCS) or mastectomy. BCS is 
appropriately used for regional or localized cancers (Jatoi and Proschan 2005). 
More than half of the female patients diagnosed with early stage breast caner 
undergo BCS while among women diagnosed with late stage of breast cancer, 
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60% undergo mastectomy (Siegel et al. 2012). Among the early stage female 
breast cancer patients who undergo BCS, the majorities receive adjuvant 
treatment: radiation therapy alone or radiation along with chemotherapy. For 
the patients diagnosed with late stage breast cancer, most of them undergo 
chemotherapy in addition to surgery and other therapies.  
There are three main groups of medications used as adjuvant treatment in 
breast cancer: hormone treatment, targeted therapy and other chemotherapy.  
 
1.2.5.2 Hormone antagonism  
Hormones including estrogen and progesterone have been implicated in the 
pathogenesis of breast cancer, due to their significant contribution to cell 
growth, differentiation and function in mammary gland (Weinberg et al. 2005, 
Abdulkareem and Zurmi 2012). The detection of ER and PR has become a 
routine test in breast cancer diagnosis, because of their therapeutic 
implications. The two main approaches of hormone treatment are blocking the 
binding of hormone to their receptors and inhibiting the production of 
hormone.    
Selective estrogen receptor modulators (SERM) act as receptor binding 
competitors of estrogen and block their effect. Tamoxifen is the most 
commonly used SERM, which antagonizes the effects of estrogen (Cole et al. 
1971). These modulators bind to the ligand-binding domain of the estrogen 
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receptor, causing a conformational change, which is different from that 
produced by estrogen. This change prevents the binding of co-activators, 
blocking the trans-activation function of the receptors (Singh and Kumar 
2005). Tamoxifen is the traditional anti-estrogen drug in hormone treatment of 
breast cancer. However, its use is becoming limited due to side effects and 
drug resistance in some breast cancers.  
Fulvestrant is an ER antagonist with no agonist effects, which has higher 
affinity to the ER and is more efficient than tamoxifen. It functions by down 
regulation and degradation of ER and is often used following anti-estrogen 
therapy in ER positive patients (Kansra et al. 2005).  
Aromatase inhibitors can block the production of estrogens from androgens as 
well as from other tissues and sites by blocking the enzyme involved in its 
biosynthesis. They are commonly used in post-menopausal women (Aguas et 
al. 2005).  
 
1.2.5.3 Targeted therapy 
Targeted therapies are using a certain type of drugs that target specific 
characteristics of tumor cells. Tamoxifen can also be grouped into targeted 
therapy since tamoxifen specifically targets estrogen receptor. Generally, there 
are two types of targeted therapies in treatment of breast cancer: monoclonal 
antibodies and inhibitors of catalytic kinase domains.   
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Monoclonal antibodies bind specifically to their target agents on tumor cells, 
and induce cell death, block cell growth or inhibit their spreading (Wicki and 
Rochlitz 2012). Herceptin is a monoclonal antibody directed towards HER2, 
which is an important stimulator of breast cancer cells. Inhibition of HER2 in 
HER2 positive patients enhances the effects of anti-estrogen treatment 
(Kurokawa et al. 2000).  
Kinase inhibitors usually bind to the ATP-binding pocket of the enzyme and 
inhibit its catalytic reaction, thus blocking signals needed for tumor growth 
(Wicki and Rochlitz 2012). For instance, Lapatinib is a tyrosine kinase 
inhibitor that inhibits the effects of HER2.  
 
1.2.5.4 Chemotherapy  
In breast cancer treatment, besides hormone and targeted therapies, there are 
other chemotherapies that use cytotoxic drugs to inhibit the growth of tumor 
cells. The commonly used cytotoxic chemotherapies include alkylating agents 
(e.g. cyclophosphamide), anthracyclines (e.g. doxorubicin) and 
anti-microtubule agents (e.g. docetaxel) (Carrick et al. 2005). The choice of 
chemotherapy is highly dependent on the type and stage of the cancer. In some 
conditions, the incorporation of different drugs results in better outcome than 
single agent.  
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The development of chemotherapy benefit breast cancer patients with longer 
and better quality life. However, their clinical usefulness is limited by the 
de-novo acquisition of resistance to these drugs (Fernandez et al. 2010). The 
approaches to overcome chemotherapy resistance mainly involve the use of 
combinations of different classes of drugs in therapy. Adjuvant therapy using 
certain inhibitors to abrogate or delay onset of resistance may also be an 
important approach.  
 
1.3 Docetaxel  
1.3.1 Introduction to docetaxel  
Docetaxel, which is synthesized from extracts of the needles of the European 
yew tree (Taxus baccata), is a member of the taxane antitumor agents (Baker 
et al. 2006). Both drugs of the taxanes, paclitaxel and docetaxel, have similar 
structures and act by binding to tubulin, thereby promoting stabilization of 
microtubules and causing cell cycle arrest. They also share similar side effects 
(Gligorov and Lotz 2004). Paclitaxel and docetaxel have been principle and 
among the most common used chemotherapeutic agents for breast cancer 
treatment (Saloustros et al. 2008). 
Compared with the first generation taxane drug paclitaxel, docetaxel presents 
some differences in their pharmacokinetics. It presents improved activity 
towards microtubule proteins with greater affinity for the tubulin-binding site 
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(Diaz and Andreu 1993), longer intracellular retention time with higher 
intracellular concentration in target cells (Riou et al 1994), and greater 
thymidine phosphorylate upregulation (Sawada et al. 1998). Also, docetaxel 
forms a different microtubule polymerization pattern (Diaz and Andreu 1993), 
and has more potent induction of BCL-2 phosphorylation and apoptosis 
(Haldar et al. 1997).  
Docetaxel is mainly metabolized in the liver by cytochrome P450 3A 
isoenzyme, which results in several pharmacologically inactive oxidation 
products (Guitton et al. 2005).   
 
1.3.2 Therapeutic applications of docetaxel in cancer therapy 
Docetaxel has been proved to be efficient in the treatment of numerous human 
cancers including prostate cancer, ovarian cancer, non-small cell lung cancer 
(NSCLC) and breast cancer (Escobar and Rose 2005, Lyseng-Williamson and 
Fenton 2005, Collins et al. 2006, Pirker and Minar 2010). Other cancers like 
gastric cancer, colorectal cancer, head and neck are also found to response to 
the drug (Caponigro et al. 2009, Nishiyama and Wada 2009).  
Combined with prednisone, docetaxel is used in the treatment of metastatic 
hormone-refractory prostate cancer. Including docetaxel in the chemotherapy 
of prostate cancer shows improvement in the outcomes compared with several 
other drug combinations (Collins et al. 2006).  
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Docetaxel has demonstrated activity in some platinum-resistance and 
paclitaxel-resistance patients. Combination of a platinum agent and a taxane is 
standard initial combination chemotherapy for advanced ovarian cancer. The 
combination of docetaxel with camptothecins is effective in the second-line 
treatment of ovarian cancer (Escobar and Rose 2005).  
Docetaxel is also proved to be efficient in the therapy of NSCLC. It can be 
used as single agent for patients with unresectable locally advanced or 
metastatic NSCLC after failure of prior platinum-based chemotherapy. In 
addition, combined with cisplatin, docetaxel is suitable for the treatment of 
patients with unresectable locally advanced or metastatic NSCLC who have 
not received prior chemotherapy (Baker et al. 2006, Pirker and Minar 2010).  
Clinical benefits of docetaxel in the treatment of breast cancer were first 
shown in the metastatic breast cancer (MBC). 20-30% breast cancer patients 
present with metastatic or locally advanced disease, while other 30% will 
develop recurrent or metastatic disease (Murray et al. 2012). Docetaxel has 
been established as an essential component of the chemotherapy for metastatic 
breast cancer. In addition, docetaxel has been incorporated into the adjuvant 
therapy of node-positive early stage breast cancer (EBC). It can be used with 
anthracyclins and herceptin if appropriate (King et al. 2009, Bedard et al. 
2010).   
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1.3.3 Mechanism of docetaxel action  
The molecular target of docetaxel is tubulin. Microtubules are hollow 
cylindrical cores composed of α and β-tubulin heterodimers. The dynamic 
instability of microtubules is the fundamental to the multiple functions of 
microtubules, especially those related with cell mitosis. The process of 
dynamic instability includes continuous addition and loss of tubulin at their 
ends (Mitchison and Kirschner 1984). Docetaxel acts by binding to a specific 
site on β-tubulin and stabilizing the formation of microtubules. In general, the 
stabilization affects the G2/M phase of the cell cycle and results in cell-cycle 
arrest. Mitotic arrest induced by taxanes is dependent on activation of the 
spindle-assembly checkpoint. Subsequently, apoptosis occurs through the 
mitochondrial pathway (Escobar and Rose 2005, Murray et al. 2012). This 
mechanism is shared by the taxanes. In addition, the microtubule inhibitor 
docetaxel also acts during S phase of cell cycle (Escobar and Rose 2005).  
Taxanes have been correlated with regulation of several key genes associated 
with the cell cycle. Many of them are specifically involved in the regulation of 
G2/M process (Murray et al. 2012). Some of well-characterized mechanisms 
of taxane include (Figure 1.3): activation of cell division control-2 kinase 
(Cdc2) (Ibrado et al. 1998); stabilization of cyclin B-1 (Yuan et al. 2006); 
activation of the spindle assembly checkpoint (Sudo et al. 2004); induction of 
apoptosis through phosphorylation of BCL-2, compared with paclitaxel, 
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docetaxel is associated with 100-fold greater phosphorylation of BCL-2  




Figure 1.3 Regulation of cell cycle in relation to taxane resistance (Murray 
et al. 2012). Taxanes have been correlated with regulation of several key 
genes associated with the cell cycle. Many of them are specifically involved in 
the regulation of G2/M process.  
 
1.3.4 Molecular mechanism of docetaxel resistance in breast cancer 
The usefulness of cytotoxic chemotherapy is limited by a common drawback, 
drug resistance. Development of drug resistance is a persistent problem that 
the treatment of local and disseminated tumors is facing. The lack of response 
to drug-induced tumor growth inhibition can be acquired through by de-novo 
refractoriness or acquired resistance (Murray et al. 2012). De-novo resistance 
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refers to a subpopulation of heterogeneous cancer cells, which are drug 
resistant while acquired resistance is associated with cellular response to drug 
exposure (Luqmani 2005).  
There are multiple potential mechanisms for chemotherapy resistance in 
cancer treatment. Principal mechanisms include (Luqmani 2005): 
a. Altered membrane transport involving the P-glycoprotein and other 
associated proteins 
b. Transformed target molecules 
c. Decreased drug activation and increased drug degradation due to change in 
expression of drug-metabolizing enzymes 
d. Drug inactivation due to conjugation with increased glutathione 
e. Subcellular redistribution 
f. Drug interaction 
g. Enhanced DNA repair 
h. Failure to apoptosis as a result of mutated cell cycle proteins (Luqmani 
2005). 
 
There are several well-characterized mechanisms of docetaxel resistance in 
breast cancer, which are included in the above list.  
 
1.3.4.1 Multidrug resistance (MDR)  
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Multidrug resistance (MDR) is a common feature of most cancer. It refers to 
the cross resistance of cancer cells to structurally unrelated cytotoxic agents. A 
key mechanism underlying MDR is associated with the over-expression of 
ATP-binding cassette (ABC) families, which act as ATP-dependent 
transporters (Dean et al. 2001).   
One of the most well studied mechanisms related with MDR is the 
over-expression of permeability-glycoprotein (Pgp) encoded by the MDR-1 
gene (Ling 1992). Pgp is a 170kDa protein containing two ATP-binding sites 
and two transmembrane domains (Ling 1992). Its expression is associated 
with resistance to multiple drugs including taxanes, vinca alkaloids, 
epipodophylotoxins and anthracylines (Murray et al. 2012). Pgp functions by 
increasing the efflux of drugs out of the cell and thus decrease the level of 
drugs within the cells to inhibit the effects of the drugs (Dumontet and Sikic 
1999). Docetaxel is the one of the substrates for Pgp-meditated efflux. 
Docetaxel binding to Pgp activates one of the ATP-binding domains and 
hydrolysis of ATP causes a conformational change in Pgp. As a result, drugs 
are released to the extracellular space (Ramachandra et al. 1998).    
ATP-binding cassette transporter family includes at least 49 members. Besides 
Pgp, other members of this family including breast cancer resistance protein 
(BCRP) encoded by ATP-binding cassette sub-family G member 2 (ABCG2) 
and multi-drug resistance related protein (MRP-1) encoded by ATP-binding 
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cassette, sub-family C member 1 (ABCC1) are also involved the multi-drug 
resistance of breast cancer (Szakacs et al. 2004).   
  
1.3.4.2  Alteration in molecular targets 
Docetaxel takes action through binding to tubulin, component of microtubule. 
Microtubules are composed of tubulin heterodimers consisting of α and 
β-tubulin subunits. They combine to form tubulin dimers in association with 
microtubule-associated proteins (MAPs). The levels of tubulin heterodimers 
and polymerized microtubule are in dynamic regulation during cell cycle 
(Kerssemakers et al. 2006). Taxanes bind to polymerized tubulin and alter the 
dynamic regulation of polymerization-depolymerization (Parness and Horwitz 
1981).  In the presence of docetaxel, the depolymerization is prevented and 
microtubule stability is thus promoted. Alteration in the molecular targets may 
be related with docetaxel resistance in cancer cells. 
β-tubulin is the direct target of docetaxel. There are as least eight β-tubulin 
isotypes in humans (Murray et al. 2012). These isotypes are different at the 
amino acid level and expression patterns. The varying distribution of β-tubulin 
within tissues suggests that differential expression may have functional 
significance (Berrieman et al. 2004). Especially, class III β-tubulin is less 
stable with an increased tendency towards depolymerization compared to 
other isotypes (Derry et al. 1997). Class III and IV β-tubulin composed 
microtubules are found to require higher ratio of paclitaxel to induce 
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microtubule stability (Derry et al. 1997). Furthermore, downregulation of class 
III β-tubulin in the cell line A549-T24 increases its paclitaxel sensitivity 
(Kavallaris et al. 1999). While upregulation of class III β-tubulin in advanced 
breast cancer has been found to be associated with paclitaxel resistance 
(Paradiso et al. 2005). These findings suggest that the increased expression of 
class III β-tubulin may a potential mechanism of taxanes. However, these in 
vitro findings may not correlate with clinical ones, since they are generated 
from experiments where taxanes are used at higher concentration and longer 
exposure than clinical use (McGrogan et al. 2008).    
Mutation of β-tubulin is another potential mechanism of taxane resistance in 
breast cancer. Mutations in β-tubulin can lead to changes in microtubule 
dynamics and stability as well as binding of cytotoxic agents. With tubulin 
mutations at drug-binding sites, the interaction between tubulin and paclitaxel 
is weak and cancer cells are resistant to cytotoxic drugs (McGrogan et al. 
2008).  
Other potential mechanisms related with microtubule alteration in taxane 
resistance of breast cancer include increased expression of tubulin, alteration 
in the expression of MAPs (Murray et al. 2012).  
 
1.3.4.3 Cell cycle regulation and docetaxel resistance  
As mentioned in the action mechanism of docetaxel part, the spindle assembly 
checkpoint (SAC) of the cell cycle is critical in the docetaxel induced cell 
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death. Defects in the SAC and other cell cycle related regulation may be 
related with the mechanisms of docetaxel resistance. 
Mad1, Mad2, BubR1 and Bub proteins are checkpoint proteins of SAC. In the 
action process of taxanes, the drug stabilizes microtubules and influences the 
formation of mitotic spindle. The spindle assembly checkpoint is activated and 
cells arrest at mitosis (Yu 2002). Decreased mitotic checkpoint function can 
result in increased taxane resistance (McGrogan et al. 2008). Inhibition of 
Mad2 and BubR in breast cancer cell line leads to increased paclitaxel 
resistance with corresponding reduced cyclin-dependent kinase-1 (cdk1) 
(Sudo et al. 2004). Other studies also highlight the importance of other 
checkpoint proteins like MAD1, BUB3 in microtubule function. Abrogation of 
these proteins can lead to a compromised spindle checkpoint and anti-mitotic 
drug resistance (McGrogan et al. 2008). 
Cyclin A and cyclin E are important mediators of S-G1 phase transient and 
subsequent G1-S phase transient. Cyclin A in involved in the regulation of 
cdk1 (Cdc2). Cdc2 plays a critical role in taxanes’ sensitivity because of its 
function in mitosis and SAC function (Takahashi et al. 2005).   
Breast cancer susceptibility gene 1(BRCA1), a tumor suppressor gene with 
multiple roles including DNA-repair, is implicated in the SAC control. 
BRCA1 plays an important role in regulation of cell stress response, which 
implicates its potential role in the chemoresistance that affect the mitotic 
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spindle. In the presence of BRCA1, breast cancer cells are more sensitive to 
the taxane-induced apoptosis, while its downregulation confers drug resistance 
(Lafarge et al. 2001, Quinn et al. 2003). BRCA1 is also involved in the 
regulation of Mad2 and BubR1 suggesting its role in the taxane drug 
resistance (McGrogan et al. 2008).  
In cell cycle regulation, HER2 may mediate taxane resistance through two 
main approaches. The overexpression of HER2 transcriptionally upregulates 
p21WAF1/Cip1, which is associated with the kinase p34cdc2, thus inhibiting 
taxane-induced p34cdc2 activation and apoptosis at the G2/M phase leading to 
drug resistance (Yu et al. 1998). HER2 may also induce taxane resistance by 
directly phosphorylating Cdc2, resulting in resistant to apoptosis and delaying 
entry into M phase (Tan et al. 2002). In addition, stimulation of HER2 has 
been shown to increase the expression of Pgp, resulting in increased drug 
resistance (Tan et al. 2002).  
 
1.3.4.4 Failure of apoptosis 
In the action of docetaxel, inducing cell death through apoptosis is the last step. 
Failure of apoptosis may reduce the effects of drugs and cause 
chemoresistance. There are mainly two pathways leading to apoptosis: 
intrinsic pathway and extrinsic pathway. The intrinsic pathway is stimulated 
by multiple factors including cell cycle and DNA damage (Brady and 
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Gil-Gomez 1999). In the extrinsic pathway, plasma membrane receptors are 
activated by the binding of ligands to death receptors on the cell membrane 
(Longley and Johnston 2005).    
BCL-2 family proteins are key regulators of the intrinsic pathway. BCL-2 
family includes pro-apoptosis and anti-apoptosis proteins. The anti-apoptosis 
subfamily consists of BCL-2, BCL-xL and Mcl-1. They function by blocking 
the release of pro-apoptosis molecules into cytosol (Gross et al. 1999). The 
ratio of pro-apoptosis and anti-apoptosis BCL-2 proteins determines whether 
cells survive or undergo apoptosis. When treated with docetaxel, BCL-2 
anti-apoptosis proteins are phosphorylated and apoptosis is induced (Berchem 
et al. 1999). Some studies indicate that over-expression of BCL-2 and BCL-xL 
contributes to taxane resistance (Murray et al. 2012). Other mechanisms that 
inhibit the phosphorylation of BCL-2 may also be related with docetaxel 
resistance (McGrogan et al. 2008).  
Nuclear factor kappa B (NF-κB) is a transcription factor, which plays a role in 
promoting cell proliferation and inhibiting apoptosis. It is involved in the 
regulation of multiple anti-apoptosis genes including BCL-2 and BCL-xL. 
NF-κB is activated in many breast cancers indicating that inhibition of NF-κB 
may sensitize tumor cells to taxanes (Mabuchi et al. 2004). Increased 
expression of Akt is observed in many breast cancers. As Akt appears to 
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regulate expression of BCL-2 and increase the activation of NF-κB, it is 
implicated in chemoresistance of docetaxel (Bratton et al. 2010).  
 
1.4 Doxorubicin 
1.4.1 Introduction to doxorubicin  
Doxorubicin is an anthracycline antibiotic, which was developed in the 1960s. 
Since then, doxorubicin has been widely used in the treatment of a number of 
tumors including leukemia and solid tumors like lung and breast cancers 
(Leonard et al. 2009).  
Side effects limit the use of doxorubicin in cancer treatment. Its most serious 
adverse effect is related with cardiac toxicity. A number of anthracycline 
derivatives have been developed to improve its efficacy and reduce toxicity 
(Leonard et al. 2009). In recent clinical treatment of cancer, liposomal 
doxorubicin was developed, which favors drug accumulation at the tumor sites 
because liposomes can exit the bloodstream at site of leaky vasculature easily 
but not the circulation in healthy tissues (Swenson et al. 2001).  
 
1.4.2 Doxorubicin and breast cancer 
Doxorubicin has been considered as one of the most effective cytotoxic agents 
in breast cancer treatment. Doxorubicin is widely used as single first-line 
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  29	  
treatment or in combination with other anticancer drugs like taxanes as 
systemic chemotherapies for the treatment of breast cancer (Cobleigh 2011).  
As a cytotoxic agent, doxorubicin interacts with DNA by intercalation and 
inhibition of macromolecule biosynthesis. This interaction inhibits the 
progression of topoisomerase II. Doxorubicin stabilizes the enzyme after it has 
broken the DNA chain for replication. As a result, the helix is prevented from 
being resealed and subsequent replication is stopped (Fornari et al. 1994).  
Resistance to doxorubicin is a barrier to successful outcomes in the treatment 
of breast cancer. Multidrug resistance has been proved to be involved in the 
drug resistance of doxorubicin. Permeability-glycoprotein (Pgp), which is 
encoded by the MDR-1 gene, can detect the binding of doxorubicin and results 
in drug resistance. Pgp increases the efflux of doxorubicin out of the cell and 
results in decreased level of doxorubicin within the cell. Downregulation of 
MDR-1 effectively restores drug sensitivity in a paclitaxel 
doxorubicin-resistant cell line (Ueda et al. 1987). In addition, it has been 
shown that increased resistance to doxorubicin is attributed to the 
HER2/PI3K/Akt pathway (Knuefermann et al. 2003). As a transcription factor 
involved in promoting cell proliferation and inhibiting apoptosis, NF-κB has 
been proved to be upregulated following treatment with doxorubicin, leading 
to reduced chemotherapy-induced apoptosis in vitro (Baldwin 2001). This 
mechanism is also involved in the docetaxel resistance.  
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1.5 Trefoil factor proteins 
1.5.1 TFF family proteins 
The mammalian trefoil factor family (TFF) contains three members, TFF1, 
TFF2 and TFF3.  
 
1.5.1.1 Structure and discoveries  
TFFs are so named because of the disulphide bond configuration of the trefoil, 
which is called P domain. This domain forms a three-leaved structure 
analogous to a trefoil or clove leaf  (Figure 1.4) (Thim and May 2005, Perry 
et al. 2008).  Each P domain is composed of a conserved sequence of 42-43 
amino acid containing six cysteine amino acid residues with essentially 
conserved spacing to form disulphide bonds resulting in the characteristic 
trefoil structure (Perry et al. 2008). TFF2 contains two trefoil domains while 
TFF1 and TFF3 contains single domain. The genes for all the three TFFs are 
located on human chromosome 21q22.3. They have similar regulatory 
sequences in the 5’-flanking regions, indicating that they may be regulated in a 
coordinated way (Regalo et al. 2005).  
TFF2 was the first discovered TFF protein. It was found in porcine pancreas 
during purification of insulin and was named pancreatic spasmolytic 
polypeptide (PSP) because its inhibitory effect on gastric motility and acid 
secretion (Jorgensen et al. 1982, Jorgensen et al. 1982). TFF1 was later found 
in a search for genes regulated by estrogen in the breast cancer cell line 
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MCF-7 and described as human breast cancer associated peptide 2 (hpS2) 
(Prud'homme et al. 1985).  TFF3 was the last known member. The peptide 
was cloned from rat intestinal epithelial cells in a search for proteins related 
with the regulation of proliferation and differentiation among intestinal 
epithelial populations, and was thereby named intestinal trefoil factor (ITF) 
(Suemori et al. 1991). In 1988, Thim proposed pS2 and PSP into a new family 
of growth factor-like peptides, which was termed as the TFF families (Thim 
1989), and TFF3 was included later. 
 
Figure 1.4 Structure of Human TFF1 (Perry et al. 2008). It contains a 
trefoil domain formed by disulphide linkage between six cysteine residues. 
There is a seventh cysteine residue at the carboxyl-terminal end, which 
facilitates homodimerizaiton or intermolecular interaction with other proteins.  
 
 
1.5.1.2 Expression and function in normal tissues  
TFF proteins are primarily expressed in mucin-secreting goblet cells, 
suggesting a relationship between their functions and that of mucins. TFFs are 
mainly expressed in the gastrointestinal tract (Kjellev 2009). The expression 
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patterns of the three TFFs are not identical. TFF1 is mainly expressed in the 
stomach and colon. TFF2 is predominantly localized in the stomach, while 
TFF3 is principally expressed in intestines (Perry et al. 2008). Besides the 
gastrointestinal tract, TFF expression has also been discovered in other tissues, 
especially in tissues that contain mucus-secreting cells like salivary, prostate 
and female reproductive organs as well as in milk (Kjellev 2009). Widespread 
expression of TFFs suggests multiple functions.  
TFFs play a central role in the gastrointestinal tract mucosal regeneration and 
protection. During gastrointestinal injury, TFFs are upregulated and secreted 
in an autocrine manner. They act as motogens to facilitate cell migration into 
the lesion. As a result, a protective barrier is formed in the process of 
restitution. Additionally, TFFs are found to be potential inhibitors of apoptosis 
and prevent anoikis during cell migration (Taupin and Podolsky 2003).  
 
1.5.2 TFF1 
 TFF1 molecule contains 60 amino acids and single trefoil domain. It also 
exists naturally as dimer (Kjellev 2009). As mentioned above, TFF1 was 
found as an estrogen regulated gene in a breast cancer cell line. Besides 
classical estrogen regulation, the expression of TFF1 is also regulated by 
growth factors such as autocrine human growth hormone (hGH), insulin like 
growth factor-1 (IGF-1), fibroblast growth factor (FGF) and epidermal growth 
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factor (EGF) (Baus-Loncar and Giraud 2005, Jackerott et al. 2006). For 
instance, the expression of TFF1 is upregulated in response to autocrine hGH 
expression in MCF-7 cells and GH administration has been found to enhance 
TFF1 transcription in gastric cells (Taupin et al. 1999, Baus-Loncar and 
Giraud 2005).  
Recent evidence has indicated the potent role of TFF1 in the development and 
progression of human tumors. Abundant work has been focused on the role 
TFF1 in gastric cancer, but the results are contradictory. There are 
accumulating evidence that supports TFF1 to be oncogenic in gastric cancer. 
TFF1 mRNA was detected in half of the human gastric cancers and some 
gastric cancer cell lines (Milne et al. 2006). The expression of TFF1 is 
increased in gastric cancer with nodal metastasis (Milne et al. 2006). On the 
contrary, some experiments proved TFF1 to be a cancer suppressor. 30% of 
TFF1 knockout mice developed gastric adenoma in one study (Taupin and 
Podolsky 2003). Since TFF1 plays a role in the restitution and regeneration, it 
is still unclear whether the development of tumor is caused by the loss of 
TFF1 mediated mucosal protection. TFF1 is usually not expressed in colon 
mucosa. Its expression in most of the colorectal tumors suggests its potential 
involvement in the development of colorectal carcinoma (Welter et al. 1994). 
It has been demonstrated that TFF1 stimulates the progression of colorectal 
adenocarcinoma by promoting cell survival, anchorage-independent growth 
and invasion (Rodrigues et al. 2006). The potential role of TFF1 in metastasis 
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also attracts attention. Cell migration and invasion are vital processes in tumor 
metastasis. TFF1 stimulates migration and invasion in human gastric 
carcinoma cells (Perry et al. 2008). Recently, TFF1 has also been found to 
enhance metastasis of prostate carcinoma (Bougen et al. 2012).  
TFF1 is a classical estrogen regulated gene and locally expressed at low levels 
in human mammary gland. Increased TFF1 expression is observed in a high 
percentage of mammary carcinoma cases (Amiry et al. 2009). Clinical studies 
indicated the correlation between TFF1 and micrometastatic breast cancer as 
well as breast cancer metastatic to bone (Weigelt et al. 2004, Smid et al. 2006). 
TFF1 has been demonstrated to enhance the oncogenicity of mammary 
carcinoma cell both in vitro and in vivo. Forced expression of TFF1 in MCF-7 
and T47D cells enhances their oncogenic capacity by increasing cell 
proliferation and survival, promoting migration and invasion, and enhancing 
other oncogenic characteristics. TFF1 also enhances in vivo tumor progression 
(Amiry et al. 2009).  
 
1.5.3 TFF3  
The peptide contains 59 amino acids and a single trefoil domain. TFF3 dimer 
has been detected in colonic tissue and gastric mucus (Kjellev 2009). The 
dimers are formed through intermolecular disulfide bonds between the seventh 
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cysteine residues at the carboxyl terminus of the peptides. Dimers are thought 
to be more active than monomers (Emami et al. 2004).  
Firstly cloned from rat intestinal epithelial cells, high expression of TFF3 is 
detected in the apical part of the goblet cells in the small and large intestine. 
Relatively low expression is detected in stomach and endocrine pancreas 
(Kjellev 2009). There is also TFF3 mRNA in duct luminal cell of normal 
mammary gland (Chin et al. 2006). The concentration of TFF3 is reported to 
vary during pregnancy.  
 
1.5.3.1 TFF3 in cancer 
There are accumulating evidence indicating the important role of TFF3 in 
tumor development and progression. The overexpression of TFF3 is observed 
in a variety of human malignancies including mammary, gastric, prostate, 
hepatocellular, and endometrial carcinomas (Kannan et al. 2010).  
It has been demonstrated that TFF3 is an independent predictor of poor 
prognosis in gastric cancer (Emami et al. 2004). TFF3 is identified to express 
in 44% to 55% of gastric cancer (Emami et al. 2004, Dhar et al. 2005). Female 
patients are more likely to express TFF3 in gastric cancer. The overall survival 
of gastric cancer in female patients is negatively correlated with TFF3 (Dhar 
et al. 2005). Recently, two independent studies confirmed serum TFF3 as a 
stable biomarker for gastric cancer screening and diagnosis (Aikou et al. 2011, 
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Kaise et al. 2012). In addition, anti-sense TFF3 in a TFF3-expressed gastric 
cancer cell line inhibits cell growth (Chan et al. 2005).  
TFF3 is expressed both in normal colonic tissues and colon tumors. TFF3 has 
been demonstrated to enhance migration and invasion of human colon 
carcinoma cells (Rivat et al. 2005), and resistance to apoptosis (Emami et al. 
2004). In addition, loss of TFF3 is related with tumor necrosis (Taupin et al. 
1996).  
However, another study suggests an inverse association between TFF3 and 
tumor progression. Their results showed marked down-regulation 
of TFF3 expression in adenomatous polyposis, then TFF3 expression returns 
to about control level during adenoma (Taupin and Podolsky 2003).  
 
1.5.3.2 TFF3 in breast cancer 
TFF3 mRNA is detected in the duct luminal cell of normal mammary gland. 
Its expression is increased in both in situ and invasive carcinoma. Although 
the mechanism is not fully understood, the correlation between TFF3 
expression and breast cancer is established by a number of clinical findings. In 
all investigated cases, increased TFF3 expression is observed in all ductal 
carcinomas in situ, lobular carcinomas in situ, invasive lobular carcinomas and 
in most of the invasive ductal carcinomas (Emami et al. 2004, Regalo et al. 
2005). TFF3 RNA has been regarded as marker for screening of ER-negative 
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and PR-negative breast cancer (Taupin et al. 1996). It can also be used to 
predict micrometastatic breast cancer (Weigelt et al. 2004). TFF1 and TFF3 
are found to strongly correlate with breast cancer metastatic to bone (Smid et 
al. 2006). Both of them are among a signature of genes that are expressed in 
breast cancer but not in blood and bone marrow (Bosma et al. 2002). In 
addition, TFF1 and TFF3 can serve as markers for the detection of 
disseminated mammary carcinoma (Lacroix 2006). Similar to TFF1, TFF3 is 
also an estrogen-regulated gene. The expression of TFF3 and ER has also been 
correlated (May and Westley 1997). Meanwhile, TFF1 and TFF3 also 
coregulate each other in a positive feedback loop (Taupin et al. 1999).  
Besides the enhancement of TFF1 in oncogenicity of mammary carcinoma 
cells, previous work of our lab shows that TFF3 is also oncogenic in breast 
cancer cell lines (Kannan et al. 2010). Forced expression of TFF3 increases 
cell proliferation and survival, promotes migration and invasion, enhance 
oncogenicity of MCF-7 cells. Depletion of TFF3 reduces oncogenicity of 
mammary carcinoma cells. In addition, functional antagonism of TFF3 
reduces cell viability in vitro and inhibits xenograft growth.  
  
1.5.3.3 The role of TFF3 in drug resistance of cancer treatment  
Besides the role in development and progression of multiple cancers, TFF3 
has also been demonstrated to be involved in drug resistance. It is observed 
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that inhibition of TFF3 expression in human gastric cancer cell line induces 
chemosensitivity to doxorubicin (Chan et al. 2005). A TFF3-expressed human 
gastric cancer cell line, SNU-1 was chosen and the expression of TFF3 was 
knocked down. The cell growth of TFF3 knockdown cells was inhibited with 
slow growth and increased apoptosis. Meanwhile, the cells show increased 
sensitivity to doxorubicin.  
Upregulated TFF3 is found to correlate with a high risk of relapse in colorectal 
cancer after chemoradiotherapy in a recent study (Casado et al. 2012).  In 
vitro experiments show that DLD-1 cells stably expressing TFF3 are 
significantly less sensitive to 5-fluorouracil and show upregulation of genes 
involved in the transcriptional machinery and resistance to apoptosis (Casado 
et al. 2012).  
Correlation of TFF3 with drug resistance has also been observed in breast 
cancer. Kaplan–Meier analysis of patients with estrogen receptor-positive 
breast cancer treated with tamoxifen has demonstrated that elevated TFF3 
mRNA expression is strongly correlated with reduced disease-free survival 
(Miller et al. 2005). As an estrogen regulated gene, the expression of TFF3 is 
negatively correlated with pathologic complete response, which is defined as 
the disappearance of all invasive cancer cells in the breast, after neoadjuvant 
chemotherapy with paclitaxel plus carboplatin (Chen et al. 2011). In addition, 
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TFF3 is observed to express in most of the drug resistant patients in this study 
(Chen et al. 2011).   
Published data of our group has demonstrated that TFF3 reduces anti-estrogen 
drug resistance in mammary carcinoma. Both tamoxifen and fulvestrant are 
classical anti-estrogen drugs of breast cancer. TFF3 has been demonstrated to 
reduce sensitivity to these drugs both in vitro and in vivo (Figure 1.5). 
Inhibition of TFF3 in tamoxifen-resistant cells improves their sensitivity to 
tamoxifen (Kannan et al. 2010). Moreover, it has been suggested that TFF3 
functions by increasing expression of BCL-2 (Kannan et al. 2010), which is 
involved in mediating a number of survival pathways (Kim et al. 2005). Thus, 
TFF3 may be considered as a novel therapeutic target of mammary carcinoma.  
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Figure 1.5 Forced expression of TFF3 reduces tamoxifen sensitivity of 
MCF-7 cells in vivo (Kannan et al. 2010).  MCF7-Vec and MCF7-TFF3 
cells were implanted into the mammary fat pad of athymic nude mice. The 
tumor xenografts were treated with estrogen or estrogen plus tamoxifen. (A) 
The growth of MCF7-Vec and MCF7-TFF3 tumors with or without tamoxifen 
(TAM). (B, C) Tumor proliferation and apoptosis were evaluated. (D) 
Histologic staining. Circle A indicates the region of perineural invasion; 
circles B and C, regions of vascular invasion. 
 
1.6 Aims of this study  
Drug resistance is a barrier in cancer therapy. Although anticancer drugs are 
becoming more and more effective, development of drug resistance has also 
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become common. Getting better understanding about the mechanisms of drug 
resistance can provide possible solutions to this problem.  
TFF3 has been demonstrated to be oncogenic in a number of cancers. Its role 
in enhancing oncogenicity in mammary carcinoma cell lines has been well 
studies. Meanwhile, its role in chemoresistance of cancer treatment attracts 
attention. TFF3 mediates anti-estrogen resistance in a BCL-2 dependent 
manner in breast cancer and blocking TFF3 induces doxorubicin sensitivity in 
a gastric cancer cell line. Besides anti-estrogen resistance, BCL-2 is also 
involved in a number of other anticancer drug resistances including docetaxel.   
Given the previous findings, which correlate TFF3 with chemoresistance, the 
main aim of this study is to investigate:  
• The role of TFF3 in oncogenicity of mammary carcinoma cells, 
• The role of TFF3 in cytotoxic drug resistance, 
• Potential mechanism underlying TFF3 mediated cytotoxic drug 
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2.1.1 General Chemicals and Reagents 
 
Table 2.1 List of Chemicals and Reagents 
Chemicals/ Reagents Source 
100bp DNA ladder Gnedirex, LV USA 
2-Mercaptoethanol  Sigma, MO USA 
30% Acrylamide-Bis Solution  Bio-Rad, CA USA 
Agarose  Bio-Rad, CA USA 
Alamar blue  Invitrogen, CA USA 
Ammonium persulfate (APS) Sigma, MO USA 
Ampicillin Sigma, MO USA 
Bovine serum albumin (BSA) Sigma, MO USA 
Dimethyl-sulphoxide (DMSO) MP Biomedicals，Illkirch, France 
DC protein assay reagents Bio-Rad, CA USA 
Ethanol  Merk, Darmstadt Germany 
Fetal Bovine Serum (FBS) Biowest, Nuaillé France 
FuGENE 6 Transfection reagents Promega, WI USA 
G418 Sigma, MO USA 
Gelred Nucleic Acid Stain Biotium, SF USA 
Glycine Bio-Rad, CA USA 
Hipure Plasmid Maxiprep Kit Invitrogen, CA USA 
Hygromycin B Invitrogen, CA USA 
Hydrochloric acid  Sigma, MO USA 
Laemmli Sample Buffer Bio-Rad, CA USA 
Isopropanol Merk, Darmstadt Germany 
Matrigel  BD, NJ USA  
Methanol  Merk, Darmstadt Germany 
Milk powder Fontevva, SDE Malaysia 
Penicillin-Streptomycin solution Biowest, Nuaillé France 
PVDF membrane Bio-Rad, CA USA 
Platinum PCR SuperMix High Fidelity Invitrogen, CA USA 
Protein marker Gnedirex, LV USA 
Proteinase inhibitor  Sigma, MO USA 
RNeasy Mini Kit Qiagen, Hilden Germany 
RPMI 1640 medium Nacalai Tesque, Kyoto Japan 
Sodium dodecyl sulfate (SDS) 1st BASE, Singapore 
Super Script cDNA Synthesis Kit  Invitrogen, CA USA 
SuperSignal West Pico 
Chemiluminescent Substrate 
Thermo, IL, USA 
Tris  1st BASE, Singapore 
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Trypsin  Biowest, Nuaillé France 
Tween-20 Sigma, MO USA 
 
 
2.1.2 Drugs and Inhibitors 
 
Table 2.2 Drugs and Inhibitors 
Drugs/ Inhibitors Stock  Source  
Docetaxel 1mmol/ml Santa Cruz 
Doxorubicin 1mmol/ml Santa Cruz 
YC137 100 µmol/ml Santa Cruz 
 
 
2.1.3 Antibodies  
 
Table 2.3 Primary Antibodies 
Antibodies  Ration Source  
β-actin 1:5000 Santa Cruz 
TFF1 1:2000 Santa Cruz 
TFF3 1:1000 Santa Cruz 
 
Table 2.4 Secondary Antibodies 
Antibodies  Ration Source  
Anti-mouse 1:5000 Sigma 





Table 2.5 RT-PCR Primer sequences 
Gene  Sequence  Annealing 
Temperature (oC) 
Cycle  












TFF3 F: GGCTGTGATTGCTGCCAG 
R: GTGGAGCATGGGACCTTTAT 
60 34 
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  44	  
2.1.5 Plasmids 
The pIRES vector (Clontech, CA, USA) was a mammalian expression vector 
used for construction of TFF3 overexpression plasmid.  pIRES or 
pIRES-TFF3 transformed cells can be selected in medium containing  the 
antibiotic G418. This vector contains an ampicillin resistance gene that can be 
used for transformed bacteria selection in plasmids amplification.  
pSilencer 2.1-U6 hydro vector (Invitrogen, CA USA) was used for 
construction of TFF3 knockdown plasmid. This vector also contains an 
ampicillin resistance gene that can be used for transformed bacteria selection 
in plasmids amplification. Transformed breast cancer cells can be selected in 
medium containing Hygromycin B.  
           
 
Figure2.1 Map of the pIRES vector.   
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Figure 2.2 Map of pSilencer 2.1-U6 hydro vector. 
 
2.1.6 Cell line  
The human mammary carcinoma cell line, MCF-7 was obtained from the 
American Type Culture Collection (Manassas, VA, USA). MCF-7 was a 
Breast cancer cell line derived from a pleural effusion of an infiltrating ductal 
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2.2 Methods  
2.2.1 Cell culture and assays  
2.2.1.1 Cell culture 
Tissue culture work was all performed in laminar flow hoods（Gelman, 
Singapore） under sterile conditions. 
All cells were cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS) and 1%Penicillin-Streptomycin solution at 37°C in a 5% 
CO2 humidified atmosphere incubator (Thermo Scientific, CO, USA). 
Medium was changed every 3 days. Cells were passaged by trysinization with 
trypsin when they reach 80-90% confluence.  
Storage of cell lines 
To store cells, cells were trypsinised and resuspended in complete medium 
and centrifuged. Supernatant was taken out and cells were resuspended in 
freezing medium (90%FBS+10%DMSO). 1ml freezing medium containing 
cells were plated into each cryogenic vial. All vials were placed into an 
isopropanol containing freezing container (Nalgene, CO, USA) and placed 
into an -80°C freezer （Thermo Scientific, CO, USA）for at least 24 hours. 
Eventually, frozen cells were stored in liquid nitrogen for long-term storage.  
Revival of cell lines 
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Cells stored in cryogenic vial were thawed in 37 °C water bath immediately. 
5ml warm complete medium was mixed with cell aliquots and centrifuged 
using a centrifuger (Eppendorf, NY, USA) to wash away the freezing medium. 
Cell pellet was resuspended with complete medium, transferred into a T25 
flask and cultured in the incubator. Medium was changed the next day.  
Cell counting 
Cell pellet was resuspended in 5ml medium. 20µl of the cell suspension was 
transferred to an Eppendorf tube and mixed with 80µl of medium. Cells were 
counted using a haemocytometer. The number of cells contained in 4 
quadrants of 9 squares was counted (twice). The counted squares were then 
added together and averaged, upon which the resulting number was used to 
determine the amount of cells/ml using the following formula: 
(Cells per 4 quadrants/4) X 10000 X dilution factor = cells /ml 
Cells/ml X final volume = total no. of cells 
 
2.2.1.2 Transfection and selection of stably transfected cells 
Transfection of plasmids was performed using the reagent of Fugene6 
according to the product manual instructions. Stable transfection required 
following selection of transfectants.  
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Transfection  
Cells were plated in T25 flasks one day before transfection. Adjust the cell 
concentration so that they would achieve the desired density of 50-80% 
confluence when transfection was performed. For each flask, 200µl serum-free 
RPMI medium was mixed with 9µl Fugene6 and incubated at room 
temperature for 5 minutes. Then the mixture was mixed with 3µg plasmid 
(ratio 3:1) and incubated for another 15minutes. During this time, medium was 
removed from the culturing flasks and washed with PBS. 3 ml serum-free 
RPMI medium was added to each flask. Fugene/Plasmid mixture was added to 
the cells drop-wise with the plate swirled all the time. After incubation of 4-8 
hours, 1ml complete medium was added to each flask. 24 hours after 
transfection, the medium containing the transfection mixture was replaced 
with complete RPMI medium.  
Selection  
To generate cell line stably expressed TFF3 or siTFF3, MCF-7 cells were 
transfected with pires-TFF3 or psilencer-TFF3 plasmids as well as empty 
vectors as controls using the transfection method described above. A flask of 
wild type cells was prepared as a control at the same time.  
48 hours after transfection, stable transfectants were selected with RPMI 
medium containing 600 µg/ml G418 (for pires-TFF3) or 200 µg/ml 
Hygromycin B for 14-21 days. Medium was changed every 2 days or later 
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every 3 days. After control wild type cells all dead, continue selection was 
preformed for a few days. Cell lines were expanded and stored for later use.  
 
2.2.1.3 Generation of drug-resistant cells  
Cells were seeded in T25 flasks 24h before addition of drug, so that they 
would reach 60-70% confluent on the day of drug adding. Resistance cells 
were selected in medium containing IC50 dose of drug. Half of the cells were 
stored when they reach confluent. The left cells were in continued drug 
selection. At the same time, control cells were cultured in medium containing 
only solution (e.g. DMSO).    
 
2.2.1.4 Three-dimensional (3D) culture of cells in Matrigel 
Growth factor reduced Matrigel was thawed overnight at 4°C before use. 
Before the experiment, a 96-well plate was filled with the Matrigel (20-40 
µl/well) and placed in an incubator at 37°C for 30 minutes to allow the 
basement Matrigel to solidify.  
Cells used for the experiment were trypsinised and resuspended in complete 
medium and centrifuged at 800 rpm for 3 minutes. The cell pellet was 
resuspended in 3ml complete medium and pipetted at least 20 times to prepare 
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the single cell suspension. The concentration of the cell suspension was 
determined using haemocytometer and adjusted by mixing with complete 
medium. 1000 cells in 100µl complete medium (RPMI medium containing 10% 
FBS) was added into each well of the 96-well plate with the solidified 
Matrigel basement. The plate was placed in the incubator for 10-20 minutes 
for the cells to settle down. Then 100 µl of 4% Matrigel in serum free medium 
per well was added to the plate, making a final concentration of 5% FBS and 2% 
Matrigel.  
Cells were cultures in a 5% CO2 humidified incubator at 37°C for 10-12 days. 
On day 4, mediumwas removed and replaced with medium containing 5% 
FBS, 2% Matrigel and drug. The replacement was repeated on every 3 or 4 
days. On the last day, the medium was removed and replaced with 100µl 
medium containing 10% Alarm Blue and incubated in the incubator for 4 
hours. After incubation, the plate was immediately read 
spectrofluorometrically using the Microplate reader (Tecan, Männedorf, 
Switzerland).  
 
2.2.1.5 Colony formation in Soft Agar 
0.5% and 0.7% agarose powder was separately added to serum-free medium 
and heated by microwave just before use. 50 µl 0.5% basement agarose gel 
was added into each well of a 96-well plate and placed in the incubator to 
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settle and solidify. 0.7% agarose gel was prepared and incubated at 42°C in a 
heat block (Eppendorf, Eppendorf, NY, USA). An equal amount of complete 
medium was also warmed up to 42 °C.  
Cells used for the experiment were trypsinised and resuspended in complete 
medium and centrifuged at 800 rpm for 3 minutes. The cell pellet was 
resuspended in 3ml complete medium and pipetted at least 20 times to prepare 
the single cell suspension. The concentration of the cell suspension was 
determined using haemocytometer. 50000 cells were add into 500µl warm 
complete medium and mixed with 500µl 0.7% agarose by pipette 3 times 
quickly. 100 µl of the mixture containing 5000 cells and 0.35% agarose was 
added to each well of the 96-well plate with agarose gel basement. The plate 
was placed in the incubator for 30 minutes for the agarose mixture to settle 
down. Then 150µl complete medium was added to each well of the plate.  
On day4, the medium was replaced with complete medium containing drug. 
Cells were cultures in a 5% CO2 humidified incubator at 37°C for 10-14 days 
with changing the medium every 3 or 4 days. On the last day, the medium was 
removed and replaced with 100µl medium containing 10% Alamar Blue and 
incubated in the incubator for 4 hours. After incubation, the plate was 
immediately read spectrofluorometrically.  
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2.2.1.6 Drug dose response  
The IC50 of drugs for cells were determined using drug dose response 
experiment. 
Cells used for the experiment were trypsinised and resuspended in complete 
medium and centrifuged. The cell pellet was resuspended in 3ml complete 
medium and pipetted at least 20 times to prepare the single cell suspension. 
The concentration of the cell suspension was determined using 
haemocytometer. Five thousand cells in 100µl medium were added into each 
well of the 96-well plate. 24 hours later, 100µl complete medium containing 
different concentration of drug was added into the cells.  
After 24, 48 or 72 hours, the medium was removed and replaced with 100µl 
medium containing 10% Alamar Blue and incubated in the incubator for 4 
hours. After incubation, the plate was immediately read 
spectrofluorometrically. IC50 was calculated based on the readings.  
 
2.2.2 Molecular Biology methods 
2.2.2.1 Plasmid transformation  
Plasmids were amplified by transforming into a DH5α strain of Escherichia 
coli. Tubes containing bacteria DH5α were taken out from -80 °C and placed 
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on ice for a while. Plasmids were mixed with DH5α bacteria and incubated on 
ice for 30 minutes. At the same time, a negative control that contained only 
bacteria DH5α was prepares. Transformation was performed using a 
heat-shock method by placing the mixture of bacteria and plasmids in a 42 °C 
water bath (Gcsellschaft for Labortechnik, Burgwedel, Germany) for 90 
seconds, immediately followed by cooling on ice for 5 minutes. One milliliter 
of LB Broth was added to each sample and incubated in the 37 °C shaker 
(Infors hc, Bottmingen Switzerland) for 1 hour. The following procedures 
were carried out in a bacteria hood (Gelman, Singapore). Cultures were 
spreaded on LB agar plates containing antibiotics. Ampicillin was used in 
selection of bacteria transformed with the plasmid of pIRES and pSilencer 
2.1-U6 hydro. After the bacterial plates were incubated in the 37 °C incubator 
(Thermo Fisher Jouan, CO, USA) overnight (about 20 hours), a single colony 
from each plate was picked and plated in 200 ml of LB Broth containing 50 
µg/mL Ampicillin. Cultures were grown at 37 °C with vigorous shaking 
overnight.  
 
2.2.2.2 Plasmids extraction  
Extraction and purification of plasmid from transformed DH5α bacteria was 
performed using the Hipure Plasmid Maxiprep Kit (Invitrogen, CA, USA).  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  54	  
Cells were harvested by centrifuging (Tomy Koygo, Tokyo, Japan) the 
overnight LB culture at 4000g for 10 minutes. All medium was removed. Ten 
milliliters buffer R3 with Rnase A was added to the pellet and the cells were 
resuspended until homogeneous. Ten milliliters buffer L7 was added and 
mixed gently until the lysate mixture was thoroughly homogeneous. The 
mixture was then incubated at room temperature for 5 minutes. Ten milliliters 
buffer N3 was added and mixed. The mixture was centrifuged at 12000g for 
10 minutes. The HiPure Filter Maxi Column was equilibrated while the cell 
lysate was prepared. The Column Holder to support a HiPure Filter Maxi 
Column was placed in the mouth of a flask. Thirty milliliters EQ1 buffer was 
applied directly into the Maxi Column. The solution in the Column drained by 
gravity flow. The supernatant from the cell lysate preparation step was 
transferred into the Maxi Column and run through the filter. The flow-through 
was discarded. The column was washed with 60 ml buffer W8. Fifteen 
milliliters buffer E4 was added to the column and drained into a 50-ml 
centrifuge tube. Fifteen and a half milliliters isopropanol was added to the 
elution tube and mixed well. The tube was then centrifuged at 12000g for 30 
minutes at 4°C. The supernatant was discarded and the pellet was air-dried for 
10 minutes. The DNA was resuspended in 500µl water and collected in a 
1.5ml eppendorf tube. The concentration of the plasmid was measured using 
Nanodrop Spectrophotometer (Thermo Scientific, CO, USA). The plasmid 
could be stored in -20°C for later use.  
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2.2.2.3 RNA extraction 
Cells were plated in 6-well or T25 flasks. Harvest cells when they reach 70-80% 
confluence. Cells were collected and centrifuged at 800g for 3min. Cell pellet 
was washed with PBS and centrifuged again. After removing supernatant, 
total RNA would be isolated using RNeasy Mini Kit from Qiagen according to 
the product manual instructions. 
Buffer RLT was freshly prepares by adding 10µl β-mercaptoethanol per 1ml 
buffer RLT before use. Cell pellet was disrupted in buffer RLT and 
homogenized using pipette. One volume of 70% ethanol was added to the 
homogenized lysate. The hole was then loaded to the spin column that was 
provided in the kit. RNA would be bound to the membrane of the spin column. 
The rest part of the mixture was efficiently washed away with buffer RW1 and 
buffer RPE. Total RNA was then eluted in 30-50µl Rnase-free water. All 
binding, washing, and elution steps were performed by centrifugation in a 
microcentrifuger. The concentration was determined using Nanodrop 
Spectrophotometer (Thermo, CO, USA). The purity of the RNA was 
determined with the ratio of A260/280 and A260/230. RNA was kept on ice 
for immediate use or stored at -80°C for later use.  
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2.2.2.4 Reverse Transcription (RT)-PCR 
cDNA was synthesized using the Super Script cDNA Synthesis Kit from 
Invitrogen. A cDNA synthesis reaction included 1µg total RNA, 5X RT 
Reaction Mix (5µl) and 10X Enzyme Mix (2µl), water to 20µl. The contents 
of the tube were gently mixed and incubated at 25°C for 10 min, later at 65°C 
for 60 min and was terminated at 95°C for 5 min. The cDNA was kept on ice 
for immediate use or stored at -20°C for later use.  
Polymerase chain reaction (PCR) was carried out using the Platinum PCR 
SuperMix from Invitrogen. Tubes and solutions were placed on ice. To set up 
a 50µl reaction, 45µl Platinum PCR SuperMix, 2µl primers mix and 2µg 
template cDNA were added to each reaction vessel. The reaction size may be 
adjusted as desired. 20µl was also an often-used reaction size. Usually, a 
negative control including component similar to normal reaction except 
template cDNA was included.  
The components in the vessels were mixed well and put into the PCR machine 
(Biometra, Goettingen, Germany). The program was set as following: 
a. Initialize at 94°C for 10 minutes to denature the template and activate the 
enzyme 
b. Perform 25–35 cycles of PCR amplification:  
   Denature: 94°C for 15–30 seconds  
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   Anneal: 55°C for 15–30 seconds  
   Extend: 72°C for 1 minute per kb 
c. Final Elongation for another 10 minutes to end the reaction 
d. Hold at 4 °C  
 
2.2.2.5 DNA agaroese gel electrophoresis 
PCR product analysis was carried out by DNA agarose gel electrophoresis. 1.5% 
agarose power was dissolved in 1XTBE buffer containing 0.01% Gel Red to 
make the agarose gel. PCR product was mixed with loading dye and the 
loaded into the well of the gel. A 100bp DNA ladder was used as a molecular 
weight marker. Electrophoresis was carried out at 80- 100 V for 20-40 min. 
The expression levels were visualized using Trans UV on the Gel Doc System 
from Bio-Rad. 
 
2.2.3 Protein methods  
2.2.3.1 Protein extraction  
Cells were collected when they reach 70-80% confluence by trypsinization 
and centrifuging. Cell pellets were washed with cold PBS and resuspended in 
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RIPA lysis buffer. The tubes were placed on ice and vortexed every 5 minutes. 
Lysates were centrifuged for 10 minutes at 13200 rpm. The supernatant was 
then collected.  
 
2.2.3.2 Protein concentration measurement 
The concentration of the protein was measured using DC protein assay from 
Bio-Rad in a 96-well plate.  
Firstly, a standard curve was prepared each time the assay was preformed. 
Two dilutions of a protein standard containing from 0.5mg/ml to 10mg/ml 
protein were prepared. Twenty-five microliters of reagent A was added into 
each well. Protein standard and samples were pipetted into wells of the plate. 
Then 200µl reagent B was added into each well and mixed. If bubbles form, 
pop them with a clean, dry pipet tip. After 15 minutes, absorbance was read at 
750 nm. The standard curve was plotted based on the standard absorbance. 
The concentration of protein samples was calculated from the standard curve.   
 
2.2.3.3 Western blot   
Protein sample and SDS-polyacrylamide gel preparation 
Protein samples were mixed with 2X Laemmli sample buffer (50µl 
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2-Mercaptoethanol was added to 9502-Mercaptoethanol sample buffer before 
use) and heated at 99 °C for 10 minutes.  
SDS-polyacrylamide gels were cast before use. They can be kept in water at 
4°C several days for later use. The components of resolving gel were 6-15% 
acrylamide, 0.375 M, pH 8.8 Tris-HCl, 0.1% SDS, 0.05% APS and 0.05% 
TEMED. The stacking gel was composed of 4% acrylamide, 0.125M, pH6.8 
Tris-HCl, 0.1% SDS, 0.05% APS and 0.1% TEMED.  
Polyacrylamide gel electrophoresis (PAGE) and transfer 
Protein samples were loaded into the gel system. Electrophoresis was carried 
out in Laemmli running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 
8.3) at constant voltage of 80-120 for 1-3 hours. After Electrophoresis was 
completed, the gel was taken out. At the same time, the Polyvinylidene 
Difluoride (PVDF) membrane was incubated in methanol for 1 minute. Then 
the membrane, filter papers and fiber pads were incubated in freshly made 
transfer buffer (48mM Tris, 39mM glycine, 0.037% SDS and 20%methanol) 
for 5 minutes. The transfer cassette was assembled as following: black side 
black side of the gel holder cassette; pre-wetted fiber pad; pre-wetted filter 
paper; gel; membrane; prewetted filter paper; pre-wetted fiber pad; red side of 
the gel holder cassette. The proteins in the gel were transferred onto the PVDF 
membrane at 30mA fro 1.5 hours. Transfer was then preformed at 4°C. 
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Western blot analysis 
After transfer was completed, the PVDF membrane was blocked in PBS-T 
containing 5% milk at 4°C overnight. 
After blocking, the membrane was incubated with appropriate primary 
antibody for at least 2 hours at room temperature on a shaker (Labnet, NJ, 
USA).  Then the membrane was rinsed 3 times with PBS-T for 10 minutes 
each to remove unbound antibodies. HRP-conjugated secondary antibodies in 
blocking buffer were used for incubation of the membrane for 1 hour. Later, 
the unbound secondary antibodies were removed by washing the membrane 3 
times with PBS-T for 10 minutes.  
Secondary antibodies bond to the membrane were detected using West Pico 
Chemiluminescent Substrate according to the manufacturer’s instruction. The 
X-ray film was developed using a Kodak film processor.  
To remove the antibodies bound to the membrane, the membrane was stripped. 
The membrane was washed with PBS-T, stripped in stripping buffer for 30 
minutes and washed with PBS-T again. Then the membrane could be 
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Chapter 3 Results  
3.1 Generation of MCF7-TFF1 stable cells 
Both TFF1 and TFF3 have been demonstrated to enhance oncogenicity of 
mammary carcinoma (Amiry et al. 2009, Kannan et al. 2010). The potential 
role of TFF1 in metastasis also attracts attention. Thus, I intended to 
investigate the role of TFF1 in EMT and metastasis of breast cancer.  
In order to investigate the potential role of TFF1 in breast cancer, I attempted 
to generate cell lines with forced expression of TFF1 or depletion of TFF1 by 
transient transfection and stable transfection. The expression of TFF1 was 
increased after transient transfection with pIRES-TFF1 plasmids (Figure 3.1A). 
However, MCF-7 cells transiently transfected with TFF1 siRNA did not 
exhibit any differences in TFF1 expression compared with MCF7-siVector 
cells (Figure 3.1B). TFF1 was depleted with transient transfection of RNAi 
duplex instead of generating stable cells previously in our group (Amiry et al. 
2009). The knockdown efficiency of the siRNA has not been tested before. 
Further work needs to be done to improve transfection efficiency or use other 
TFF1 siRNA sequences that have been reported to successfully knockdown 
TFF1 in mammary carcinoma cells.  
To generate stable cells expressing TFF1, MCF-7 cells were stably transfected 
with expression vector pIRES containing the entire TFF1 gene or empty 
vector pIRES as a control, and selected with G418. MCF-7 cells stably 
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transfected with pIRES vectors or pIRES-TFF1 were designated as 
MCF7-Vector and MCF7-TFF1 respectly. Two groups of cells were selected. 
In the first group, TFF1 mRNA and protein levels of MCF7-TFF1 and 
MCF7-Vector did not exhibit differences (Figure 3.2A and B).  For the 
second group, the TFF1 protein level of MCF7-TFF1 was much higher 
compared with MCF7-Vector (Figure 3.2D) although the difference was not 
shown in their mRNA level (Figure 3.2C). However, following total cell 
number experiment showed that MCF7-TFF1 cells did not demonstrate an 
increased cell number compared with MCF7-Vector, which was not consistent 
with previous findings (Amiry et al. 2009). Due to the reasons that negative 
control was not used in the western blot and the size of the detected band 
cannot be precisely confirmed because it was below all the markers, the 
western blot result might not be reliable.  
Due to the technical difficulties in generating MCF7-TFF1 stable cells, I 
decided to focus on the role of TFF3 in breast cancer.  
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Figure 3.1 Transient transfection of TFF1 or siTFF1 into MCF-7 cells. 
MCF-7 cells were transfected with TFF1 or siTFF1 with transient transfection.  
(A) Transient transfection with TFF1 expression vector or empty vector for 48 
hours. RT-PCR was used to exam the efficiency. (B) Transient transfection 
with siTFF1 expression vector or empty vector. RT-PCR was used to exam the 
efficiency.  
             
          
 
Figure 3.2 Attempts in generation of MCF7-TFF1 stable cells. Two 
MCF7-TFF1 positive cell-lines were selected by G418. The mRNA and 
protein levels of TFF1 of the first cell line were examined using RT-PCR (A) 
and western blot (B). The mRNA and protein levels of TFF1 of the second cell 
line were examined using RT-PCR (C) and western blot (D).  
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3.2 Forced expression of TFF3 enhanced oncogenicity of MCF-7 cells  
Previously, a cell model was established to determine the functional role of 
TFF3 in human mammary carcinoma cells in our lab. An ER-positive cell line, 
MCF-7 was transfected with an expression vector containing TFF3 or the 
empty vector as a control. After selection with G418, the cells that stably 
expressed TFF3 or empty vector were kept for further use. The mRNA levels 
of TFF3 in MCF7-TFF3 and MCF7-Vector cells were determined by RT-PCR, 
confirming that MCF7-TFF3 exhibits higher level of TFF3 expression (Figure 
3.3A). Previously, Dr. Vijay Pandey from our group, generated the stable cells, 
and confirmed that MCF7-TFF3 expressed higher level of TFF3 protein than 
MCF7-Vector using western blot.   
TFF3 has been demonstrated to be oncogenic in mammary carcinoma cells 
(Kannan et al. 2010). Soft agar and Three-Dimensional (3D) Matrigel cell 
growth were performed to see if TFF3 could enhance oncogenicity of MCF-7 
cells. One of the important features of oncogenic transformation is 
anchorage-independent growth, which can be evaluated by colony formation 
in soft agar (Elenbaas et al. 2001). Cells were seeded in 0.35% agar gel with 
0.5% base gel in a 96-well plate for 8 days. Forced expression of TFF3 in 
MCF-7 cells stimulated anchorage-independent growth, which was reflected 
in more and larger colonies as well as higher fluorescence in alamar blue 
detection (Figure 3.3B).  
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3D Matrigel cell culture can also used to indicate the effect of certain genes on 
cancer cell growth (Benton et al. 2009).  Both cell lines were grown in the 
3D culture of laminin-rich matrix gels. Colonies of the MCF-7 cells with 
forced expression of TFF3 were more and larger compared with MCF7-Vector 
cells. Meanwhile, increased cell growth was indicated with higher cell 
viability (Figure 3.3C).  
These results indicated that forced expression of TFF3 increased colony 
formation in soft agar and cell growth in 3D Matrigel, suggesting that 
forced expression of TFF3 promoted oncogenicity in MCF-7 cells.   
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Figure 3.3 Forced expression of TFF3 enhanced oncogenicity of MCF-7 
cells. (A) The overexpression of TFF3 is confirmed in TFF3 forced expressed 
MCF-7 stable cells by RT-PCR. (B) Anchorage-independent growth was 
evaluated in soft agar in full medium in a 96-well plate. (C) MCF7-Vector and 
MCF7-TFF3 cells were cultured in 2% Matrigel and 5% FBS medium in a 
96-well plate. Cell growth was indicated using alamar blue. Pictures of 




3.3 Forced expression of TFF3 enhanced oncogenicity of MCF-7 cells in a 
BCL-2 dependent manner 
As an anti-apoptotic protein, BCL-2 is involved in mediating a number of 
survival signaling pathways in cancer cells (Czabotar et al. 2009). It has 
previously been demonstrated that BCL-2 is upregulated by the forced 
expression of TFF3 in MCF-7 cells (Kannan et al. 2010).  
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YC137 was used to specifically inhibit BCL-2. The influence of BCL-2 
inhibition on cell behaviour was determined by colony formation in soft agar 
and cell growth in 3D Matrigel culture. From the results, it could be observed 
that YC137 decreased colony formation of MCF7-TFF3 cells in soft agar 
whereas the colony formation of MCF7-Vector cells was not significantly 
affected (Figure 3.4A). Inhibition of BCL-2 with YC137 reduced cell growth 
in 3D-Matrigel of both MCF7-Vector and MCF7-TFF3 cells. YC137 reduced 
Matrigel cell growth of MCF7-TFF3 cells to that observed in MCF7-Vector 
cells without treatment (Figure 3.4B). In other words, YC137 partially 
abrogated the TFF3-enhanced matrigel growth of MCF-7 cells. In addition, it 
was observed that BCL-2 mRNA level was higher in MCF-7 cells with TFF3 
forced expression, compared with vector control cells (Figure 3.4C). It has 
been previously demonstrated that forced expression of TFF3 also increased 
the protein level of BCL-2 (Kannan et al. 2010).  
These results suggest that TFF3 stimulated anchorage-independent growth and 
cell growth in 3D Matrigel, at least partially, in a BCL-2-dependent manner 
and supported previous finding that TFF3-stimulated anchorage-independent 
growth is BCL-2-dependent (Kannan et al. 2010).   
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Figure 3.4 TFF3 stimulated colony formation in soft agar and 3D 
Matrigel cell growth in a BCL-2 dependent manner. (A) MCF7-Vector and 
MCF7-TFF3 cells were seeded in 0.35% agar in a 96-well plate and treated 
with BCL-2 inhibitor YC137. (B) MCF7-Vector and MCF7-TFF3 cells were 
cultured in 2% Matrigel and 5% FBS medium in a 96-well plate and treated 
with YC137. (C) The expression level of BCL-2 was evaluated with RT-PCR.  
* P< 0.05, ** P<0.01, *** P<0.001 .  
 
 
3.4 Forced expression of TFF3 reduced Docetaxel sensitivity of MCF-7 
cells  
3.4.1 TFF3 reduced Docetaxel sensitivity of MCF-7 in monolayer culture 
Besides enhancing oncogenicity of mammary carcinoma cells, TFF3 has also 
been proved to correlate with anti-estrogen resistance of breast cancer in a 
BCL-2 dependent manner (Kannan et al. 2010). Since BCL-2 is involved in 
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the mechanisms of both tamoxifen and docetaxel resistance (Berchem et al. 
1999, Kim et al. 2005), the correlation of TFF3 with docetaxel resistance of 
breast cancer was investigated. 
MCF7-TFF3 and MCF7-Vector cells were grown in 96-well plates and treated 
with different dose of docetaxel. After 48 hours of treatment, cell viability was 
measured using alamar blue. As indicated in Figure 3.5, cell responses were 
significantly different. Cell growth of both cell lines was inhibited by 
docetaxel in a dose dependent manner. However, compared with MCF-Vector 
cells, forced expression of TFF3 significantly reduced docetaxel sensitivity in 
MCF-7 cells.  
     
 
Figure 3.5 TFF3 promoted cell viability of MCF-7 cells in presence of 
docetaxel. MCF7-TFF3 and MCF7-Vector cells were grown in 96-well plates 
and treated with different dose of docetaxel for 48 hours. After treatment, cells 
viability was measured using alamar blue. Cells were incubated with medium 
containing alamar blue for 4 hours before fluorescence was read. **P< 0.01, 
***P< 0.001.  
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3.4.2 Forced expression of TFF3 increased IC50 of Docetaxel in MCF-7 
The half maximal inhibitory concentration (IC50) is used to measure the 
effectiveness of drugs in inhibiting biological function.  
Based on readings obtained from separate experiments of monolayer cell 
culture with different doses of docetaxel, the IC50 of docetaxel in 
MCF7-Vector and MCF7-TFF3 cells was calculated. The values are listed in 
table 3.1. The IC50 of docetaxel for MCF7-TFF3 cells was much higher than 
that of MCF7-Vector, suggesting that docetaxel sensitivity of MCF-7 cells 
was reduced by forced expression of TFF3.  
Table 3.1  50% Inhibitory concentrations for docetaxel in MCF-7 cell lines 
 




3.4.3 TFF3 reduced Docetaxel sensitivity of MCF-7 in 3D Matrigel cell 
growth 
In order to further investigate the effect of forced expression of TFF3 on 
docetaxel sensitivity of MCF-7 cells, MCF7-Vector and MCF7-TFF3 cells 
were grown in 3D Matrigel and treated with docetaxel. Figure 3.6A revealed 
that, docetaxel inhibited cell growth of both cell lines. Docetaxel treatment 
reduced MCF7-TFF3 cell growth to that observed in MCF7-Vector cells 
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without docetaxel treatment. Docetaxel had a greater effect on growth of 
MCF7-Vector cells with an observed reduction of 63% in cell viability, 
compared with 26% in MCF7-TFF3. Forced expression of TFF3 abrogated the 
inhibitory effect of docetaxel on cell growth in 3D Matrigel, which was also 
reflected in more and larger colonies (Figure 3.6B). Time dependent measure 
of cell growth in Matrigel clearly demonstrated that forced expression of TFF3 
abrogated the cytotoxic effects of docetaxel (Figure 3.6C).  
    
Figure 3.6 Forced expression of TFF3 reduced docetaxel sensitivity of 
MCF-7 in 3D Matrigel. (A) Cell growth in 3D Matrigel: MCF7-Vector and 
MCF7-TFF3 cells were grown in 4% Matrigel and 10%FBS medium in a 
96-well plate and treated with 10µmol/l docetaxel or vehicle for 4 days. Cell 
growth was measured using alamar blue. (B) Pictures of colony formation in 
3D Matrigel with different treatment taken under microscope. (C) 
Time-dependent response to docetaxel treatment. MCF7-Vector+docetaxel 
was compared with MCF7-Vector. MCF7-TFF3+docetaxel was compared 
with MCF7-TFF3. ***P< 0.001. 
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3.4.4 TFF3 reduced Docetaxel sensitivity of MCF-7 cells in soft agar 
colony formation assays 
Similarly, MCF7-TFF3 cells displayed a reduced sensitivity to docetaxel in 
soft agar colony formation assays. Docetaxel inhibited colony formation of 
both cell lines. Forced expression of TFF3 abrogated the inhibitory effect of 
docetaxel on colony formation in soft agar (Figure 3.7A.B). Soft agar colony 
formation was reduced 39% in MCF7-Vector cells, and 17.7% for 
MCF7-TFF3 cells. Hence MCF7-TFF3 cells were more resistant to treatment 
with docetaxel (Figure 3.7A). Figure 3.7C presents a time dependent 
measurement of cell viability in soft agar of both cells in response to docetaxel 
treatment. Compared with MCF7-Vector cells, MCF7-TFF3 displayed more 
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Figure 3.7 Forced expression of TFF3 reduced docetaxel sensitivity of 
MCF-7 in soft agar. (A) Colony formation in soft agar: MCF7-Vector and 
MCF7-TFF3 cells were grown in 0.35％ agar with 0.5% base agar gel in a 
96-well plate and treated with 10µmol/l docetaxel or vehicle (here is DMSO) 
with full serum medium for 4 days. Colony formation was measured using 
alamar blue. (B) Pictures of colony formation with different treatment taken 
under microscope. (C) Time-dependent response to docetaxel treatment. 
MCF7-Vector+docetaxel was compared with MCF7-Vector. 
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3.5 Forced expression of TFF3 reduced docetaxel sensitivity of MCF-7 
cells in a BCL-2-dependent manner  
3.5.1 TFF3 reduced docetaxel sensitivity of MCF-7 cells in a 
BCL-2-dependent manner in soft agar colony formation  
It has already been shown that forced expression of TFF3 increased BCL-2 
expression to promote anchorage-independent growth and cell growth in 
Matrigel (Figure 3.4). Previously, TFF3 has been demonstrated to mediate 
anti-estrogen resistance in mammary carcinoma cells in a BCL-2 dependent 
manner (Kannan et al. 2010). The role of BCL-2 in TFF3 stimulated docetaxel 
resistance was therefore also investigated.  
The effect of inhibition of BCL-2 with YC137 on the anchorage-independent 
growth of MCF7-Vector and MCF7-TFF3 cells in the absence and presence of 
docetaxel was examined. TFF3 significantly promoted colony formation and 
docetaxel resistance of MCF-7 cells in soft agar. However, when the cells 
were treated with docetaxel and YC137, little difference in colony formation 
was detected between MCF7-Vector and MCF-TFF3 cells. (Figure 3.8A). 
From time dependent measurement of anchorage-independent growth in 
response to docetaxel and YC137, it was also observed that the BCL-2 
inhibitor restored the docetaxel sensitivity of MCF7-TFF3 cells. These results 
indicated that the survival advantage of MCF7-TFF3 cells in response to 
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docetaxel treatment was eliminated by the inhibition of BCL-2 (Figure 3.8 A 
and B).  
 
 
Figure 3.8 Forced expression of TFF3 reduced docetaxel sensitivity of 
MCF-7 cells in a BCL-2-dependent manner in soft agar. (A) Cell growth in 
soft agar: MCF7-Vector and MCF7-TFF3 cells were seeded in 0.35% agar and 
treated with BCL-2 inhibitor YC137 alone or in combination with docetaxel. 
(B) Time dependent measure of cell growth in different treatment. 
MCF7-Vector+docetaxel+YC137 was compared with 
MCF7-Vector+docetaxel. MCF7-TFF3+docetaxel+YC137 was compared 
with MCF7-TFF3+docetaxel. The two ‘***’ represent the significance level 
between MCF7-TFF3+docetaxel+YC137 and MCF7-TFF3+docetaxel on day4 
and day6. ***P< 0.001. 
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3.5.2 TFF3 reduced docetaxel sensitivity of MCF-7 cells in a 
BCL-2-dependent manner in 3D Matrigel cell growth assays 
Cell growth of MCF7-Vector and MCF7-TFF3 cells with treatment of BCL-2 
inhibitor YC137, alone or in combination with docetaxel, was also 
investigated in 3D Matrigel. As exhibited in Figure 3.9A and B, forced 
expression of TFF3 clearly promoted docetaxel resistance in 3D Matrigel cell 
growth. MCF7-Vector and MCF7-TFF3 displayed similar response of to the 
treatment of docetaxel combined with YC137, resulting from reduced effect of 
TFF3 by inhibition of BCL-2. Results observed here were consistent with 
those observed in soft agar. The growth advantage of MCF7-TFF3 cells in 3D 
Matrigel in response to docetaxel treatment was eliminated by the inhibition of 
BCL-2. 
These findings suggest that decreased docetaxel sensitivity stimulated by 
forced expression of TFF3 is mediated by BCL-2.  
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Figure 3.9 Forced expression of TFF3 reduced docetaxel sensitivity of 
MCF-7 cells in a BCL-2-dependent manner in 3D Matrigel. (A) Cell 
growth in 3D Matrigel: MCF7-Vector and MCF7-TFF3 cells were grown in 4% 
Matrigel and 10%FBS medium in a 96-well plate and treated with BCL-2 
inhibitor YC137 alone or in combination with docetaxel. Cell growth was 
measured using alamar blue. (B) Time dependent measure of cell growth in 
different treatment. MCF7-Vector+docetaxel+YC137 was compared with 
MCF7-Vector+docetaxel. MCF7-TFF3+docetaxel+YC137 was compared 
with MCF7-TFF3+docetaxel. The three ‘***’ represent the significance level 
between MCF7-TFF3 +docetaxel+YC137 and MCF7-TFF3+ docetaxel on 
day4 and day6 as well as between MCF7-Vector+docetaxel+YC137 was 
compared with MCF7-Vector+docetaxel on day6. *P<0.05, ***P< 0.001.  
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3.6 Depletion of TFF3 increased Docetaxel sensitivity of MCF-7 cells  
To further investigate the role of TFF3 in the docetaxel resistance of 
mammary carcinoma cells, TFF3 was depleted using siRNA. As I was unable 
to successfully generate stable clones within the period of my enrolment, I 
obtained the cells from Dr. Vijay Pandey in our group. Generally, MCF-7 was 
transfected with pSilencer-siTFF3 or the empty vector as a control. After 
selection with Hygromycin, the cells that stably expressed siTFF3 or empty 
vector were kept for further use. The efficiency of TFF3 depletion was 
confirmed by RT-PCR (Figure 3.10A). The mRNA level of MCF7-siTFF3 
was lower than MCF7-siVector. Dr. Vijay Pandey had confirmed that 
MCF7-siTFF3 expressed lower level of TFF3 protein than MCF7-siVector.   
In my experiments, siTFF3 did not reduce soft agar colony formation of 
MCF7-siTFF3 cells compared with control cells. However, depletion of TFF3 
by siRNA increased the sensitivity of MCF-7 cells to docetaxel in soft-agar 
colony formation assays (Figure 3.10B). The depletion of TFF3 reduced 
growth of MCF-7 cells in 3D Matrigel. However, in this experiment, 
docetaxel treatment did not significantly affect cell growth of either 
MCF7-siVector or MCF7-siTFF3 cells in Matrigel (Figure 3.10C). Hence, the 
dose of docetaxel used in 3D Matrigel assays may need to be increased to 
observe an effect in this assay system. Cell sensitivity to various 
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chemotherapeutic agents is well known to be determined by the 
microenvironment (Kleinman, Martin 2005).  
 
 
Figure 3.10 Depletion of TFF3 increased docetaxel sensitivity of MCF-7 
cells. (A) RT-PCR was used to see the expression of TFF3 in MCF7-Vector 
and MCF7-TFF3 after TFF3 knockdown with siRNA. (B) Cell growth in soft 
agar: MCF7-siVector and MCF7-siTFF3 cells were seeded in 0.35% agar and 
treated with docetaxel. (C) Cell growth in 3D Matrigel: MCF7-siVector and 
MCF7-siTFF3 cells were grown in 4% Matrigel and 10%FBS medium in a 
96-well plate and treated with docetaxel. Cell growth was measured using 
alamar blue. *P<0.05, NS, not significant.  
 
 
3.7 TFF3 was upregulated in Docetaxel-resistant MCF-7 cells 
Besides detecting docetaxel sensitivity after forced expression or depletion of 
TFF3, the relationship between TFF3 and docetaxel resistance was also 
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analysed by examining TFF3 expression in docetaxel-resistant mammary 
carcinoma cells.  
The first step was to generate docetaxel-resistant MCF-7 cells. MCF-7 cells 
were treated with 10nmol/L docetaxel and kept in selection before use. Then 
docetaxel-resistant MCF-7 cells were treated docetaxel in dose-dependent and 
time-dependent manners. Docetaxel-resistant MCF-7 cells were treated with 
10µM, 50µM and 100µM docetaxel separately for 24 hours. The protein levels 
of these cells were measured with western blot. The expression of TFF3 in 
docetaxel-resistant MCF-7 cells displayed a dose-dependent increase (Figure 
3.11A). Docetaxel-resistant MCF-7 cells that were treated with docetaxel for 5, 
9 and 14 weeks were collected for western blot. Figure 3.11B showed a 
time-dependent increase in TFF3 expression. In conclusion, TFF3 was 
upregulated in docetaxel-resistant MCF-7 cells and its expression was 
stimulated by treatment with docetaxel.   
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Figure 3.11 TFF3 was upregulated in Docetaxel-resistant MCF-7 cells. (A) 
Docetaxel-resistant MCF-7 cells were treated with different dose of docetaxel 
for 24 hours, the concentrations of docetaxel was labeled in the figure. The 
expression levels of TFF3 were detected using western blot after treatment.  
(B) The expression levels of TFF3 in MCF-7 cells after treatment with 
docetaxel. MCF7-DR-P1 cells were treated with docetaxel for 5 weeks. 
MCF7-DR-P2 cells were treated for 9 weeks. MCF7-DR-P3 cells were treated 
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3.8 Forced expression of TFF3 reduced Doxorubicin sensitivity of MCF-7 
cells  
3.8.1 TFF3 reduced Doxorubicin sensitivity of MCF-7 in monolayer 
culture 
Besides docetaxel, doxorubicin is another commonly used cytotoxic 
chemotherapy in breast cancer treatment. As a cytotoxic agent, doxorubicin 
interacts with DNA and subsequently stops replication (Fornari et al. 1994). It 
has been demonstrated that inhibition of TFF3 expression in human gastric 
cancer cells increases chemosensitivity to doxorubicin (Chan et al. 2005). The 
role of TFF3 in doxorubicin resistance of MCF-7 cells was investigated. 
MCF7-Vector and MCF7-TFF3 were grown in 96-well plates and treated with 
different doses of doxorubicin. After 48 hours of treatment, cell viability was 
measured using alamar blue. As indicated in Figure 3.12, cell responses of 
MCF7-Vector and MCF7-TFF3 to doxorubicin were different. Cell viability 
of both cell lines was inhibited by doxorubicin in a dose dependent manner.  
Forced expression of TFF3 reduced doxorubicin sensitivity in MCF-7 cells, 
compared with MCF-Vector cells. It is noted that while the differences were 
statistically significant, the actual biological differences were small. 
 
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  83	  
      
Figure 3.12 TFF3 promoted cell viability of MCF-7 cells in presence of 
doxorubicin. MCF7-TFF3 and MCF7-Vector cells were grown in 96-well 
plates and treated with different dose of doxorubicin for 48 hours. After 
treatment, cells viability was measured using alamar blue. Cells were 
incubated with medium containing alamar blue for 4 hours before fluorescent 




3.8.2 Forced expression of TFF3 increased IC50 of Doxorubicin in MCF-7 
IC50 of doxorubicin in MCF7-Vector and MCF7-TFF3 cells was used to 
indicate the effect of TFF3 on doxorubicin resistance. Both MCF7-Vector and 
MCF7-TFF3 cells were treated with different doses of doxorubicin and cell 
viability was measured using alamar blue staining. IC50 of doxorubicin in 
MCF7-Vector and MCF7-TFF3 cells were calculated base on the readings.  
The values are listed in Table 3.2. The IC 50 of doxorubicin for MCF7-TFF3 
cells was higher than that of MCF7-Vector, suggesting that doxorubicin 
sensitivity in MCF-7 cells was reduced by forced expression of TFF3.  
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Table 3.2  50% Inhibitory concentrations for doxorubicin in MCF-7 cell 
lines 





3.8.3 Effect of TFF3 on doxorubicin sensitivity of MCF-7 cells 
The effect of forced expression of TFF3 on doxorubicin sensitivity of MCF-7 
cells was investigated using soft agar colony formation and cell growth in 3D 
Matrigel. Doxorubicin inhibited colony formation in soft agar and cell growth 
in 3D Matrigel of MCF7-Vector and MCF7-TFF3 (Figure 3.13A and B). 
Colony formation in soft agar assay showed that MCF7-TFF3 cells were more 
resistant to treatment with doxorubicin and indicated that TFF3 affects 
doxorubicin sensitivity of MCF-7 cells. However, no significant differences 












Figure 3.13 Forced expression of TFF3 reduced doxorubicin sensitivity of 
MCF-7. (A) Soft agar:  MCF7-Vector and MCF7-TFF3 cells were seeded in 
0.35% agar and treated with doxorubicin. (B) Cell growth in 3D Matrigel: 
MCF7-Vector and MCF7-TFF3 cells were grown in 4% Matrigel and 
10%FBS medium in a 96-well plate and treated with doxorubicin. Cell growth 
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Chapter 4 Discussion 
4.1 Generation of MCF-TFF1 stable cells 
The goal of stable transfection was to generate cells that stably express TFF1 
or TFF1 siRNA. After transfection, the cells were selected with G418 or 
hygromycin B according to drug-resistance markers in the expression vectors. 
MCF7-TFF1 and MCF7-siTFF1 stable cells were not successfully generated.  
The mRNA level of TFF1 was increased after transient transfection with 
pIRES-TFF1. However, TFF1 mRNA levels of MCF7-TFF1 and 
MCF7-Vector did not exhibit any differences after stable transfection. There 
has been a report that successfully generated MCF7-TFF1 stable cells using 
the same vectors, transfection reagent and selection condition (Kannan et al. 
2010). Since transient transfection was proved to be successful, the factor that 
contributed to failure of stable transfection might be related with the selection 
process. The majority of the cells died after selection with G418 after one 
week. Only a few colonies survived, which did not show increased expression 
of TFF1 mRNA. It was possible that the surviving cells were MCF-7 cells that 
were naturally resistant to G418 and that the cells that were transfected with 
pIRES-TFF1 died under the pressure of drug selection. In addition, the 
differences in outcomes of stable transfection might be due to the use of 
different strains of MCF-7 cells.  
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Transient transfection with TFF1 siRNA did not deplete the expression of 
TFF1 in MCF-7 cells. There were a number of potential reasons that could 
have led to failure in generation of MCF7-siTFF1 stable cells. Sequence 
design was the first step this process. The siRNA sequences used here have 
never been used before. The five TFF1 siRNA sequences were located near 
each other with overlaps in the sequence of TFF1. Designing potential 
TFF1-specific siRNA sequences scattered along the TFF1 mRNA sequence 
may provide more choices for higher efficiency of knockdown. I have used 
other TFF1 siRNA sequences that were reported to successfully and stably 
depleted TFF1 in MCF-7 cells (Buache et al. 2011). Low efficiency in 
transfection was also one of the potential reasons for failure of depletion. 
Factors that might contribute to low efficiency in transfection included 
transfection reagent, quality of plasmids and the status of cells. In addition, 
TFF1 plays a role in promoting oncogenicity and survival of mammary 
carcinoma cells. Hence, over time there may be a natural selection for cells 
with TFF1 expression. Improving quality of plasmids, using other TFF1 
expression, tranfection reagents and MCF-7 cells may be useful approaches to 
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4.2 TFF3 enhances oncogenicity of mammary carcinoma cells 
There is accumulating evidence indicating the correlation between TFF3 
expression and oncogenicity of mammary carcinoma (Emami et al. 2004, 
Regalo et al. 2005). Although the mechanism is not fully understood, a 
number of clinical studies have indicated the prognostic value of TFF3 (Perry 
et al. 2007). The expression of TFF3 has been regarded as predictor for 
multiple types of breast cancers including micrometastatic breast cancer 
(Weigelt et al. 2004), ER and PR negative breast cancer (Doane et al. 2006) 
and disseminated breast cancer (Lacroix 2006). In addition, TFF3 expression 
has been demonstrated to be associated with invasion and metastasis in 
advanced disease (Ahmed et al. 2012).  
In addition to the clinical relevance of upregulated TFF3 in mammary 
carcinoma, the functional role of TFF3 in mammary carcinoma cells has also 
been investigated. TFF3 has been demonstrated to increase mammary 
carcinoma cell proliferation and survival and enhance anchorage-independent 
growth (Kannan et al. 2010). In my studies, TFF3 has been found to promote 
colony formation in soft agar and cell growth in 3D Matrigel of MCF-7 cells 
(Figure 3.1), which is consistent with previous findings.  
Previously, BCL-2, an anti-apoptosis protein, has been shown to be 
upregulated by forced expression of TFF3 in mammary carcinoma cells 
(Kannan et al. 2010). Further experiments in my thesis demonstrated that 
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TFF3 enhanced soft agar colony formation and cell growth in 3D Matrigel in a 
BCL-2 dependent manner at least partially (Figure 3.2). BCL-2 is involved in 
cell cycle regulation and favors cell survival through blocking apoptosis 
(Gross et al. 1999). TFF3 has been demonstrated to active multiple survival 
pathways including NF-κB (Chen et al. 2000), mitogen-activated protein 
kinase (Taupin et al. 1999), phosphatidylinositol-3-kinase–Akt (Brumatti et al. 
2010) and signal transducer and activator of transcription 3 (STAT3) 
(Kinoshita et al. 2000), all of which regulate BCL-2 expression (Brumatti et al. 
2010). Therefore, it is likely that TFF3 enhances cancer cell survival through 
activating survival pathways that upregulate the expression of BCL-2. As a 
common final mediator, BCL-2 increases cell survival through preventing 
apoptosis.   
 
Figure 4.1 Forced expression of TFF3 promotes cancer cell survival 
through upregulation of BCL-2. TFF3 may enhance cancer cell survival 
through activating survival pathways that upregulate the expression of BCL-2. 
BCL-2 increases cell survival through preventing apoptosis.   
 
Besides BCL-2, qPCR analysis demonstrated that forced expression of TFF3 
appropriately regulated the expression level of some other cell-cycle related 
genes including BAX, which is pro-apoptotic, as well as CDK1 and p21 
Forced	  expression	  of	  TFF3 NF-­‐κB↑ MAPK↑ PI3K/Akt↑	  STAT3↑ BCL-­‐2↑ Cell	  survival 
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(Kannan et al. 2010). Upregulated BCL-2 should not be the only mechanism 
that contributes to the pro-survival role of TFF3.  
 
4.3 TFF3 reduces docetaxel sensitivity in mammary carcinoma cells 
Docetaxel is one of the most commonly used cytotoxic agents in mammary 
carcinoma therapy. However, drug resistance has challenged its usefulness, 
which is a common drawback of chemotherapy. There are multiple potential 
mechanisms contributing to docetaxel resistance including multidrug 
resistance, alteration in β-tubulin, cell cycle deregulation and failure of 
apoptosis (Murray et al. 2012).  
Forced expression of TFF3 has been demonstrated to reduce docetaxel 
sensitivity in MCF-7 cells in this study. Forced expression of TFF3 enhanced 
cell viability, colony formation in soft agar and cell growth in 3D Matrigel of 
MCF-7 cells with docetaxel treatment (Figure 3.3- Figure 3.5), and the IC50 
of docetaxel in MCF-7 cells was dramatically increased by forced expression 
of TFF3 (Table 3.1). Depletion of TFF3 increased docetaxel sensitivity in 
MCF-7 cells (Figure 3.8). Moreover, the expression of TFF3 was upregulated 
in MCF7 docetaxel resistant cells, and its expression was further induced by 
docetaxel (Figure 3.9).    
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Above findings suggested that forced expression of TFF3 provided a survival 
advantage for MCF-7 cells in the presence of docetaxel. The survival 
advantage was lost when TFF3 was depleted. In addition, docetaxel induced 
TFF3 expression favored survival of docetaxel-resistant cells and contributed 
to docetaxel resistance. As discussed above, forced expression of TFF3 was 
involved in regulation of several survival pathways and enhanced survival of 
mammary carcinoma cells (Kannan et al. 2010). Survival advantages through 
TFF3 related survival pathways might be one of the potential mechanisms that 
contributed to docetaxel resistance.  
 
4.4 Reduced docetaxel sensitivity in MCF7-TFF3 cells is BCL-2 
dependent 
There have been no studies published regarding the role or mechanism of 
action of TFF3 in docetaxel resistance. Although little is known about the 
mechanisms of TFF3-related docetaxel resistance, it was demonstrated here 
that BCL-2 might be involved. Forced expression of TFF3 reduced docetaxel 
sensitivity in a BCL-2 dependent manner in MCF-7 cells (Figure 3.7, 3.8).  
BCL-2 has been demonstrated to play a vital role in some of the docetaxel 
resistance mechanisms. Cell apoptosis mediates inhibition of proliferation in 
docetaxel treatment and BCL-2 is an important anti-apoptosis protein in the 
regulation of apoptosis. Docetaxel induces apoptosis through phosphorylation 
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of BCL-2, which results in inhibition of BCL-2 function (Berchem et al. 1999). 
Therefore, deregulation of BCL-2 phosphorylation may be related with 
docetaxel resistance. Some studies have indicated that overexpression of 
BCL-2 contributes to taxane resistance (Murray et al. 2012). NF-κB and Akt, 
which appear to increase BCL-2 expression, have also been implicated in 
resistance to docetaxel. In addition, studies found that TFF3 can prevent 
apoptosis in colonic epithelial cells (Taupin et al. 2000). TFF3 can activate a 
number of signaling pathways that regulate expression of BCL-2 and it has 
been demonstrated that forced expression of TFF3 enhances oncogenicity in a 
BCL-2 manner (Kannan et al. 2010). Therefore, docetaxel stimulated TFF3 
expression may favor tumor cell survival through BCL-2 related survival 
pathways.  
 
4.5 Effect of TFF3 on doxorubicin sensitivity of MCF-7 cells  
The potential role of TFF3 in doxorubicin sensitivity of mammary carcinoma 
cells was also investigated. TFF3 has been demonstrated to be functionally 
related with doxorubicin sensitivity in gastric cancer cells. Inhibition of TFF3 
in SNU-1 cells increased its sensitivity to doxorubicin (Chan et al. 2005).  In 
breast cancer, TFF3 has been demonstrated to enhance the cell viability of 
MCF-7 cells after treatment with doxorubicin and reduce doxorubicin-induced 
apoptosis (Kannan et al. 2010).  
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Data of this study indicated that forced expression of TFF3 reduced 
doxorubicin sensitivity in MCF-7 cells (Figure 3.13). The IC50 of doxorubicin 
in MCF-7 cells was increased by forced expression of TFF3 (Table 3.2). 
These findings need to be further examined. MCF7-Vector and MCF7-TFF3 
cells did not show significant differences to the treatment with doxorubicin. 
Higher concentration of cytotoxic drug may be required to significantly reduce 
the growth of MCF7-Vector cells so that the effect of TFF3 can be observed.  
Studies have observed that activation of NF-κB is required in chemoresistance 
of doxorubicin in tumor cells and its inactivation promotes 
doxorubicin-induced apoptosis (Baldwin 2001, Bottero et al. 2001). Functions 
of TFF3 have been proposed to be mediated through activation of NF-κB 
(Karin et al. 2002). Besides, forced expression of TFF3 has been demonstrated 
to upregulate anti-apoptosis genes while downregulate pro-apoptosis genes 
(Kannan et al. 2010), suggesting the potential role of TFF3 in 
doxorubicin-induced apoptosis. Forced expression of TFF3 might provide 
survival advantage through NF-κB related inactivation of apoptosis in the 
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4.6 The role of TFF3 in drug resistance of mammary carcinoma therapy  
In addition to the accumulating evidence indicating a vital role of TFF3 in 
mammary carcinoma, its potential correlation with drug resistance in cancer 
therapy also attracts attention.  
Kaplan–Meier analysis of patients with ER positive breast cancer treated with 
tamoxifen has demonstrated that elevated TFF3 mRNA expression is strongly 
correlated with reduced disease-free survival (Miller et al. 2005). Expression 
of TFF3 is negatively correlated with pathologic complete response after 
neoadjuvant chemotherapy with paclitaxel plus carboplatin (Chen et al. 2011). 
Studies in mammary carcinoma cells show that TFF3 enhances oncogenicity 
of cancer cells and reduces drug resistance of anti-estrogen drugs, docetaxel 
and doxorubicin. Although varying in structures and mechanisms of function, 
different anticancer drugs may be faced with common resistance mechanisms 
like multidrug resistance and anti-apoptosis.  Since TFF3 has been found to 
be involved in mediating multiple signaling pathways (Chen et al. 2000, 
Taupin et al. 1999, Brumatti et al. 2010, Kinoshita et al. 2000), TFF3 may 
provide a survival advantage in the presence of chemotherapy through 
activating survival pathways resulting in drug resistance. Therefore, the 
expression level of TFF3 may be regarded as a predictive marker of drug 
efficiency in some chemotherapies and targeting of TFF3 may be a novel 
therapeutic approach in breast cancer treatment.   
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4.7 Soft-agar colony formation assay and 3D-Matrigel assay  
Soft agar colony formation and 3D-Matrigel assays are important founctional 
assays used in cancer research.  
Oncogenic transformation occurs via a series of genetic and epigenetic 
alterations that yield a cell population that is capable of proliferating 
independently. Such transformation is associated with certain phenotypic 
changes such as loss of contact inhibition and anchorage independence growth. 
Anchorage independent growth is one of the hallmarks of oncogenic 
transformation, which is considered the most accurate and strigent in vitro 
assay for detecting malignant transformation of cells (Jian et al. 2001). Soft 
agar colony formation assay is a common method to monitor 
anchorage-independent growth, which measures proliferation in a semisolid 
culture media by quantification of colonies (Jian et al. 2001).  
Matrigel is a gelatinous protein mixture derived from mouse tumor cells and 
resembles the complex extracellular environment (Kleinman, Martin 2005). 
Three-dimensional Matrigel is often used to study the behavior of tumor cells. 
3D-Matrigel assay enables researchers to approximate physiological 
conditions that exist in vivo cellular environment. Since many cell behaviors 
are influenced by microenvironment, the 3D-Matrigel system is believed to be 
good predictor of in vivo activity. Besides being a measure of oncogenic 
behaviour of tumor cells, both soft agar colony formation and 3D-Matrigel 
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assays allow for analysis of the potential anti-cancer effects of potential 
inhibitor molecules.   
 
4.8 Future work 
4.8.1 TFF3 and docetaxel resistance 
• Improve siRNA mediated depletion of TFF3 
MCF7-siTFF3 stable cells with more efficient knockdown of TFF3 need to be 
generated. Furthermore using a higher concentration of docetaxel may lead to 
more convincing conclusions as to the effect of reduced TFF3 expression on 
sensitivity to chemotherapeutic agents.  
• Include other cell lines 
At present, all data that correlated TFF3 expression with docetaxel resistance 
in breast cancer cells was generated with MCF-7 cells only. Including other 
mammary carcinoma cell lines is required to support the correlation.  
• Neutralization of TFF3 by polyclonal antibody 
Besides depletion of TFF3 with siRNA, functional antagonism of TFF3 by 
TFF3 monoclonal antibody may also provide strong evidence for the functional 
role of TFF3.  
• In vivo experiments 
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The effect of forced expression of TFF3 as well as depletion of TFF3 on 
docetaxel sensitivity should be investigated in vivo using mouse xenograft 
models.  
• Depletion of TFF3 in docetaxel-resistant mammary carcinoma cells 
Docetaxel has been shown to stimulate the expression of TFF3 in 
docetaxel-resistant MCF-7 cells. Depletion of TFF3 in docetaxel-resistant cells 
and examing the docetaxel sensitivity may provide further evidence for the 
correlation between TFF3 and acquired docetaxel resistance.  
• Identify survival signaling pathways 
Although TFF3 has been demonstrated to play a role in docetaxel resistance of 
mammary carcinoma cells, the associated mechanism remains undefined. 
Screening of related genes and performing functional assays to investigate 
potential mechanisms underlying the correlation between TFF3 and docetaxel 
resistance needs to be considered.  
 
4.8.2 TFF3 and doxorubicin resistance 
TFF3 has also been found to reduce doxorubicin sensitivity in mammary 
carcinoma cells. Experiments need to be improved such that the findings on 
the interaction of doxorubicin and TFF3 observed in this thesis may become 
more reliable. Colony formation in soft agar assay showed that MCF7-TFF3 
cells were more resistant to treatment with doxorubicin. However, no 
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significant differences were observed between MCF7-Vector and MCF7-TFF3 
cells in 3D-Matrigel assays. The dose of doxorubicin used in 3D Matrigel 
assays may need to be increased to observe an effect in this assay system. Cell 
sensitivity to various chemotherapeutic agents is well known to be determined 
by the microenvironment (Kleinman, Martin 2005).  
In addition, all of the above mentioned work that has been done or planned, to 
investigate the correlation between TFF3 and docetaxel sensitivity should also 
be performed with doxorubicin to further investigate the potential role of 
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